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ABSTRACT 
The dopaminergic system is a regulatory system of the brain controlling various 
motor, cognitive and behavioral activities. Neurotransmitter dopamine (DA) plays an 
important role in modulating brain circuits controlling functions of this system with 
dopamine transporter (DAT) maintaining its homeostasis. Abnormalities in this 
homeostasis and/or nucleotide polymorphisms in the DAT structure leads to its 
association with a wide range of neurological and neuropsychiatric disorders, with 
attention-deficit hyperactivity disorder (ADHD) being one of them. 
Disrupting the normal function of DAT, many psychostimulants such as amphetamine 
(AMPH) upon being transported via DAT into the pre-synaptic neuron alters DAT 
properties triggering N-terminal DAT phosphorylation associated DA efflux.  
Recently identified, ADHD associated human DAT (hDAT) single nucleotide 
polymorphism (SNP), A559V, displayed anomalous DA efflux (ADE). Our results 
showed A559V hDAT and its rat homologue, A558V rat DAT (rDAT), displaying 
AMPH independent increased phosphorylation, including T53 site (human equivalent 
being S53), a proline directed phosphorylation site specific for rDAT, further 
unaffected by AMPH, which may support ADE observed for this polymorphism. 
These SNPs also showed reciprocal decreased palmitoylation status. With these 
modifications impacting DAT properties, we found phosphorylation driven increased 
membrane raft localization for A559V hDAT and other palmitoylation deficient 
mutants. These membrane rafts serve as a site for localization of phosphorylated DAT
xviii 
 
and a platform for DA efflux. These mutants also showed increased lateral membrane 
mobility, which was reciprocally decreased for phosphorylation deficient mutants 
(T53A rDAT, S7A hDAT and S53A hDAT) which have increased palmitoylation.  
Further, studies confirmed C581 to be a palmitoylation site in humans, with C581A 
hDAT being a palmitoylation deficient mutant having elevated phosphorylation with 
membrane microdomain and mobility properties similar to A559V hDAT. 
For A559V hDAT, the close proximity of Val substitution to the palmitoylation site 
could cause a structural alteration in DAT transmembrane spanning domain (TMD) 12 
helical structure. The bulkier substitution may mechanistically hinder C581 
palmitoylation causing its movement away from DAT core region, lose of flexibility, 
altered DAT membrane localization, mobility and function. We believe other 
phosphorylation or palmitoylation deficient mutants might show similar unknown 
mechanisms, reciprocally regulating post-translational modifications. 
With palmitoylation helping in membrane raft partitioning, stabilization of membrane 
anchoring and integral membrane protein interaction, we demonstrate palmitoylation 
to be a factor for DAT membrane mobility. We believe the palmitate group affects 
DAT’s interaction with binding partners and cholesterol and that its deficiency leads to 
increased lateral membrane mobility. This palmitoylation status could be the driving 
force for phosphorylation driven increased localization of phosphorylated DAT in 
membrane raft microdomains, leading to increased interaction with binding partners, 
serving as a platform for phosphorylation-dependent DA efflux either by AMPH-
stimulation or by polymorphism.  
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CHAPTER I 
INTRODUCTION 
Neurotransmission and neurotransmitters 
The nervous system is a complex system that plays a key role in controlling and 
coordinating neurological signal transmission as well as various voluntary and 
involuntary actions. This system is well maintained by a coordinated network of 
neurons, which communicate with each other by a process called neurotransmission. 
Neurotransmission is brought about by endogenous chemicals called neurotransmitters 
which are stored in small sac like organelles called synaptic vesicles and are released 
from pre-synaptic neurons upon being excited through an incoming signal. These 
neurotransmitters then move through neuronal junctions called synapses and are 
received and recognized by receptors present on the plasma membranes of post-
synaptic neurons, causing relaying of signals downstream and bringing about synaptic 
transmission. Following the transmission of the signals, the neurotransmitters are 
cleared from the synapses either by diffusing through the plasma membrane into the 
pre-synaptic neurons or are taken-up by the pre-synaptic neurons with the help of 
neurotransmitter specific transporter proteins or are taken-up by neighboring glial 
cells. Within the pre-synaptic neurons, these neurotransmitter substrates are 
repackaged into synaptic vesicles or are targeted towards metabolic or enzymatic 
degradation. Clearance of neurotransmitter substrates from synapses is an important 
step in maintaining synaptic homeostasis and inability to do so leads to over-
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stimulation of the post-synaptic receptors. Long term over-stimulation of these post-
synaptic receptors could lead to various neurological conditions and diseases.  
The neurotransmission cycle occurs within milliseconds and is triggered by an action 
potential generated by voltage gated ion channels which originates in the cell bodies of 
the neurons. This action potential moves across the axon terminal, causing 
depolarization of the pre-synaptic neuronal membranes leading to synaptic 
transmission. Upon reaching the end of the axon terminal, the action potential triggers 
the opening of calcium channels causing Ca
++
 ions to move from the synapse into the 
pre-synaptic neurons, in exchange for Na
+
 ions which are pumped to the extracellular 
side. This buildup of Ca
++
 ions triggers the fusion of synaptic vesicles with the plasma 
membrane causing the release of neurotransmitters into the synapse. New synaptic 
vesicles are formed by pinching off the plasma membrane within the pre-synaptic 
neurons where it is filled with neurotransmitters for cycle to continue (Fig. 1) [1]. 
Within neurons there are many different types of neurotransmitters present and one of 
the ways of classifying them is into amino acids, peptides and monoamines. Some of 
the neurotransmitters that fall into these groups are: 
 Amino acid neurotransmitters: glutamate, aspartate, D-serine, γ-aminobutyric 
(GABA) and glycine. 
 Monoamines and other biogenic amines neurotransmitters: dopamine (DA), 
serotonin (5-HT), norepinephrine (NE), epinephrine and histamine. 
 Gasotransmitters: nitric oxide (NO), carbon monoxide (CO), hydrogen 
sulphide (H2S). 
The uptake of neurotransmitter substrates from the synapses into the pre-synaptic 
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Image courtesy, 2002 Encyclopaedia Britannica Inc, with permission. 
Figure 1: Neurotransmission pathway. 
Neurotransmission is triggered by an incoming action potential which upon reaching 
the pre-synaptic neuronal terminal opens the ion channels allowing Ca
++
 ions to move 
into the cell. These Ca
++
 ions trigger the fusion of synaptic vesicles with the plasma 
membrane of the pre-synaptic neurons causing the release of neurotransmitters into the 
synapse. These neurotransmitters then act on the receptors present on the post-synaptic 
neurons, relaying the signal downstream. These neurotransmitters are then transported 
back to the pre-synaptic neurons by transporters and are either repackaged into the 
synaptic vesicles or are targeted towards metabolic or enzymatic degradation.  
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neurons is brought about by substrate specific neurotransmitter transporter (NTTs)    
proteins, which are present on the plasma membrane of the pre-synaptic neurons. 
These NTTs belong to the solute carrier 6 (SLC6) gene family which are widely 
expressed in the brain. These NTTs are also called neurotransmitter-sodium-symporter 
(NSS) or Na
+
/Cl
- 
dependent transporters and are named according to the 
neurotransmitter substrate they transport. The transport of neurotransmitter substrates 
across the transporter is brought about by an electrochemical gradient, where Na
+
 ions 
are the source of energy, generated by the Na
+
/K
+
 transporting ATPase. The uptake of 
substrate through NTTs occurs along with the co-transportation of extracellular Na
+ 
and Cl
-
 ions and in some cases intracellular K
+
 ions, with the function of NTTs being 
regulated by various protein kinases and protein-protein interactions [2-6]. 
Abnormalities in the function of these NTTs is associated with various neurological 
disorders such as attention-deficit hyperactivity disorder (ADHD, Alzheimer’s disease 
(AD), obsessive compulsive disorder (OCD), bipolar disorder (BPD), Parkinson’s 
disease (PD), X-linked mental retardation, autism and mood disorders such as 
depression and anxiety [7-9].  
Monoamine neurotransmitters 
Neurotransmitters that structurally contain an amino group connected to an aromatic 
ring by a two carbon chain are known as monoamines. These monoamine 
neurotransmitters, DA, NE and 5-HT, are transported from the synapse to the pre-
synaptic neurons with the help of dopamine transporter (DAT), norepinephrine 
transporter (NET) and serotonin transporter (SERT) respectively. DA and NE are 
derived from a common upstream amino acid Tyr with DA being the immediate 
precursor of NE, while 5-HT is synthesized from Trp. These neurotransmitters  
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together coordinate a wide range of functions including mood, attention, sleep, 
learning, memory function, obsession, sex and anxiety (Fig. 2) [10].  
Dopaminergic system 
The dopaminergic system in the brain is responsible for controlling motor, cognitive, 
and motivational behavior and plays a role in regulating sleep patterns, moods, 
attention, memory and locomotion [6, 9, 11-15]. Failure of this system leads to 
disruption of DA function that has an effect on neurological and psychological 
illnesses such as PD, AD, ADHD, BPD, drug abuse and addiction [6, 9, 16-21]. The 
dopaminergic system is categorized into four pathways called the mesocortical, 
meolimbic, nigrostriatal and tuberoinfundibular tracks within the brain. Dopaminergic 
neurons arising from different regions of the brain have different functions. The 
neurons located within the mesescephalon branch into three neuronal groups: the 
retrobulbar, the substantia nigra (SNc) and the ventral tegmental area (VTA). While 
most of the neurons arising from the zona compacta of the SNc are a part of the 
nigrostriatal pathway projecting into the dorsal striatum and are associated with 
movement, the neurons arising from the VTA are part of the mesolimbic pathway 
projecting into the limbic and its connected regions such as the nucleus accumbens, 
amygdale and hippocampus and are associated with mood, motivation, thought 
process and reward. Some of the neurons arising from the VTA are also a part of the 
mesocortical dopaminergic pathway projecting into the prefrontal, cingulated and 
perirhinal cortex. Other neurons arising from the retrobulbar area project into the 
hypothalamus and regulate the hormonal secretions from the pituitary (Fig. 3) [22-26]. 
All of these dopaminergic neurons although present within the central nervous system 
(CNS) are considered unrelated as they perform different sets of cellular functions, are 
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Image courtesy, http://elitenootropics.com/identify-overcome-low-dopamine/, with 
permission. 
Figure 2: Monoamine neurotransmitters and the functions they share. 
Monoamine neurotransmitters DA, NE and 5-HT coordinate and regulate various 
different functions individually but also are involved in coordinating a wide range of 
functions together such as mood, attention, sleep, appetite, anxiety, attention, sex and 
cognitive functions.  
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Image courtesy, https://www.oist.jp/news-center/photos/dopamine-pathways, with 
permission. 
Figure 3: Dopaminergic pathways. 
Dopaminergic neurons are categorized into four pathways: mesocortical, meolimbic, 
nigrostriatal and tuberoinfundibular.   
      Mesolimbic Pathway 
Tuberinfundibular Pathway 
   Mesocortical Pathway Nigrostriatal Pathway 
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located in different positions and project differently. The only common aspect linking 
them is that they all synthesize DA. 
DAT 
DAT plays an important role in maintaining DA homeostasis. Following the release of 
DA into the synapse, DAT functions to clear the synaptic DA by uptake in presence of 
an electro-chemical gradient. Upon uptake of DA by DAT into the pre-synaptic 
neurons, it is either repackaged into synaptic vesicles for reused or is directed towards 
degradation by oxidation in the presence of monoamine oxidase (MAO) or catechol-
O-methyl transferase (COMT). This process of uptake is highly specific to the type of 
neurotransmitters [3]. DAT belongs to the SLC6 gene family and called SLC6A3 as it 
is the third member of the group. It is known to be distributed majorly in the CNS 
while some is also present in the gut [2]. 
DAT structure 
When compared to other members of the SLC6 gene family, mammalian DAT shows 
a high homology to various transporter structures like NET (~67%), SERT (~49%) 
and GABA (~45.5%) [6]. The mammalian DAT is a ~80 KDa glycoprotein. With its 
three dimensional crystallized structure still unknown, mammalian DAT is highly 
comparable to its prototype, the bacterial homologue, leucine transporter protein 
(LeuT) derived from Aquifex aeolicus which shares a 20% sequence identity to 
mammalian DAT. The three dimensional LeuT structure shows it to be a 12 
transmembrane spanning domain (TMD) helical structure arranged in two pseudo-
symmetrical inverted repeats: TMDs 1-5 and TMDs 6-10, with its N- and C-termini 
present within the cytosol. The amino acid sequence alignment between LeuT, DAT 
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and other Na
+
/Cl
- 
dependent transporters revealed that various residues are conserved 
between these transporters (Fig. 4). TMDs 1, 3, 6 and 8 form the central substrate 
binding site with TMDs 1 and 6 being anti-parallel to each other having breaks in the 
helical structure about halfway across the membrane bilayer. Other TMDs surround 
the core site, providing support to this region. The LeuT structure shows the presence 
of two Na
+
 ions near the leucine molecule at halfway across the bilayer (Fig. 5). These 
ions stabilize the LeuT core, TMDs 1 and 6 and the bound leucine molecule. Since 
leucine transport is not chloride dependent, the LeuT structure failed to show the 
presence of Cl
-
 ion near the binding pocket, but instead had a Cl
-
 ion bound near the 
surface of the protein. Many LeuT gating residues are found to be conserved in DAT 
and other Na
+
/Cl
- 
dependent transporters, all of which play a role in substrate transport 
[27-33].  
The recently crystallized eukaryotic DAT structure, Drosophila melanogaster DAT 
(dDAT) shares more than 50% sequence identity to mammalian DAT. The overall 
structure of dDAT is similar to LeuT except for the presence of a kink at the centre of 
TMD 12 as a result of P572, causing the second half of the TMD 12 to move away 
from the transporter. dDAT crystal structure predicted N-linked glycosylation sites 
and a disulphide bond in the extracellular loop 2 (EL2), critical for the trafficking of 
transporter to the plasma membrane. The binding pocket shows proximal binding of 
Na
+
 and Cl
-
 ions. Many important dDAT gating residues are found to be conserved in 
LeuT and human DAT (hDAT), playing a role in substrate recognition and transport. 
dDAT structure showed the presence of a cholesterol molecule anchored at the 
junction of TMD 5 and 7, which stabilizes DAT in an outward-open confirmation 
position (Fig. 6) [30, 34]. These transporters serve as a template in understanding the 
overall mammalian DAT structure. The mammalian DAT is also a 12 TMD structure  
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Image courtesy, Yamashita, A., et al., Crystal structure of a bacterial homologue of 
Na+/Cl- dependent neurotransmitter transporters. Nature, 2005. 437(7056): p. 215-
223, with permission [31]. 
Figure 4: Amino acid sequence alignment of A. aeolicus LeuT with hDAT 
homologues for glycine, GABA, DA and 5-HT using Psi-BLAST.  
The conserved residues are highlighted in red while α-helices and β-strands in LeuT 
are depicted in coils and arrows respectively. The open and filled triangles show 
residues involved in coordinating the Na
+
 ions, Na1 and Na2 respectively while 
residues whose side-chains interact with Na
+
 ions are further highlighted in yellow. 
The filled black circles indicate the residues involved in leucine binding and the 
residues whose side chains interact with the leucine are enclosed by purple boxes. The 
open and filled stars indicate the charged pairs at the extracellular and cytoplasmic 
entrances respectively. The residues in the LeuT dimer interface are shown in orange 
letters. For eukaryotic transporters, residues are truncated in the alignment and the 
numbers of the truncated residues are shown in parentheses. 
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Image courtesy, Yamashita, A., et al., Crystal structure of a bacterial homologue of 
Na+/Cl- dependent neurotransmitter transporters. Nature, 2005. 437(7056): p. 215-
223, with permission [31]. 
Figure 5: LeuT structure. 
LeuT is a 12 TMD spanning helical structure, with the first 10 TMD forming the 
central protein core. TMDs 1-10 are arranged in two pseudo-symmetrical inverted 
repeats in the membrane plane: TMDs 1-5 and TMDs 6-10.  Leucine residue (yellow 
triangle) is seen here in the substrate binding site accompanied with two Na
+
 ions 
(blue circles) bound in the sodium binding sites, halfway across the membrane bilayer 
in an occluded site lacking water. 
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Image courtesy, Penmatsa, A., Wang, K.H. and Gouaux, E., X-ray structure of 
dopamine transporter elucidates antidepressant mechanism. Nature, 2013. 503(7474): 
p. 85-90, with permission [30]. 
Figure 6: Drosophila DAT structure. 
dDAT is shown in the presence of  tricyclic antidepressant Nortriptyline, Na
+
 ions and  
Cl
- 
ions and a cholesterol molecule. It is a 12 TMD spanning helical structure similar 
to LeuT except for the presence of a kink at the centre of TMD 12 as a result of P572, 
causing the second half of the TMD 12 to move away from the transporter.  
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with its termini facing the cytosol and TMDs 1, 3, 6 and 8 forming the central 
substrate binding pocket [31, 35]. The hDAT is a 620 amino acid residue protein while 
the rat DAT (rDAT) is a 619 residue protein with hDAT having an extra G199. The 
rDAT differs from hDAT in 48 residues making its sequence 92% identical to hDAT. 
DAT undergoes at least four forms of post translational modifications: glycosylation, 
ubiquitination, phosphorylation and S-palmitoylation. These modifications facilitate 
the interaction between DAT and other proteins, altering DAT transport kinetics 
and/or change the distribution of DAT within the plasma membrane or between the 
cell surface and intercellular space [36-42]. Pharmacological manipulation of these 
post-translational modifications may lead to therapeutic routes to regulate DAT 
expression and function. 
Glycosylation of mammalian DAT occurs on the Asn residues present on the EL2. 
While hDAT is glycosylated on N181, 188 and 205, rDAT is glycosylated on N181, 
188, 196 and 204 (Fig. 7) [2, 35, 41, 43, 44]. Glycosylation helps stabilize DAT 
localization on the plasma membrane, maintain functional regulation, increase the DA 
Vmax and surface expression of DAT [42, 45]. It also plays an important role in 
susceptibility of DAT to the effect of drugs and disease. Ubiquitination of DAT occurs 
on the N-terminus determining if DAT internalization is temporary for it to be 
recycled back to the plasma membrane, or it is permanent leading to DAT 
degradation. Ubiquitinated DAT is sorted away from the constitutive recycling 
pathway and into a late endocytic pathway, resulting in lysosomal degradation [46, 
47].    
Phosphorylation has been widely studied on a cluster of Ser residues (2, 4, 7, 12, 13 
and 21) on the N-terminus, out of which, S7 and S13 have been validated for 
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Image courtesy, Foster, J.D. and Vaughan, R.A., with permission. 
Figure 7: Depiction of rDAT in its currently known phosphorylation and 
palmitoylation sites.  
DAT is a 12 TMD helical structure with its N- and C-termini facing towards the 
cytosol. DAT is heavy glycosylated on its EL2. The rDAT structure depicts the known 
sites for phosphorylation (on the N-terminus) and palmitoylation (on the C-terminus).   
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phosphorylation by mass spectrometry and N-DAT in-vitro phosphorylation 
respectively. Phosphorylation on these residues is brought about by protein kinases 
such as protein kinase A (PKA), protein kinase C (PKC) and calcium/calmodulin-
dependent protein kinase II (CaMKII), which play a role in mediating DA efflux [39-
41, 48-50]. Apart from these Ser residues, the other site that has been validated by 
mass spectrometry to undergo phosphorylation on N-terminus is T53 (human 
equivalent being S53). This site is phosphorylated by extracellular signal regulated 
kinase (ERK), a proline directed kinase [38, 48, 51]. Not much is known about this 
site, but its proximity to TMD 1 and intracellular gate residue R60 suggests that 
phosphorylation at this site could play a role in regulating the binding and interaction 
of DAT with other associated proteins or Src homology 3 domain proteins thus 
affecting the opening and closing of intracellular gates and ion flow or efflux [48, 50, 
52, 53].  
A protein kinase C (PKC) activator, phorbol 12-myistate, 13-acetate (PMA) has been 
associated with down-regulation of DAT, reduction in the surface expression of DAT 
and its Vmax [46, 54, 55]. While PKC- and CaMKII-mediated phosphorylation leads to 
down-regulation of DAT, clatherin and dynamin and/or lysosomal dependent 
endocytosis leading to dampening of DA uptake and AMPH-mediated DA efflux, 
ERK-mediated phosphorylation increases DA transport promoting DAT surface 
expression [46, 56-61]. 
 The role of N-terminus in phosphorylation is confirmed by truncating the first 21 
amino acid residues or deleting first 5 Ser residues on the N-terminus. This leads to 
reduction in PKC-mediated DAT phosphorylation, although it does not alter DAT 
localization, DA uptake or PKC-mediated internalization [40, 54, 56, 59, 62, 63].  
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DAT also undergoes S-palmitoylation, the reversible addition of a saturated fatty acid 
moiety (palmitate) via a thioester bond to C580 (human equivalent being C581) on the 
C-terminal rDAT, with additional sites still unidentified [36, 64]. Palmitoylation is 
known to control various functions of integral membrane proteins such as membrane 
binding, catalytic activity, trafficking, sub-cellular targeting, protein localization and 
turnover [47, 61, 65-72]. The main driving force in such a diverse role played by 
palmitoylation is the properties of the palmitate group, its hydrophobicity/membrane 
affinity and its preference for the cholesterol rich membrane rafts [71]. Loss or 
inhibition of palmitoylation strongly reduces transport Vmax, opposes turnover, 
promotes transport capacity and PKC-stimulated down-regulation also affecting DAT 
degradation and lateral membrane mobility [36, 41, 56, 72-74].   
Apart from the post-translational modifications that affect DAT function there also are 
many important amino acid residues that play a critical role in its function. Single 
nucleotide polymorphism (SNP) for these residues is seen to bring about DA efflux, 
affecting proper DAT function leading to various illnesses [8, 9, 41, 75-78].  
The transport of DA across DAT occurs via the alternating access mechanism (Fig. 8) 
[3]. In this mechanism DAT undergoes a series of conformational changes from 
outward open to inward open so as to transport the substrate from the synapse, back 
into the pre-synaptic neuron. In this mechanism, there is the movement of two Na
+
 and 
one Cl
-
 ion along with DA from outside to inside of the neuron. DAT in a polarized 
state is in an outward open conformation, during which DA, Na
+
 and Cl
-
 ions move 
into the open conformation and take their places at the S1, Na1 and Cl binding sites 
respectively, with the bound ions having a major effect on substrate binding. 
Following the binding of DA at the binding pocket, DAT moves into an outward  
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Image courtesy, Kristensen, A.S., et al., SLC6 neurotransmitter transporters: 
structure, function, and regulation. Pharmacological reviews, 2011. 63(3): p. 585-640, 
with permission [3]. 
Figure 8: Alternating access mechanism for transportation of substrate.  
A schematic representation of the conformational states in the alternating access 
mechanism for transporting substrate across SLC6 transporters. The outward facing 
conformation for the transporter allows the substrate and Na
+
 ions to bind at their 
respective binding sites. This binding triggers conformational changes within the 
transporter that makes it move into an outward facing occluded and then into an 
inward facing occluded conformation, where the extracellular and intracellular gates 
are closed. Ion interactions within the transporter leads to the opening of the 
intracellular gates and the transporter then shifts into the inward open conformation 
releasing the substrate and the ions into the cytosol. 
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facing occluded conformation, with Cl
-
 ions balancing the charge between the co-
transported, DAT bound DA and Na
+
 ions. Since the presence of intracellular Cl
- 
ions 
positively regulates DAT turnover, Cl
-
 ions plays an important role in the 
conformational shift of DAT from outward occluded to inward occluded 
conformation. Once the S1, N1 and Cl sites are occupied, the second Na
+ 
ion binds at 
the N2 binding site. This leads to the coupling between the Cl
-
 and Na
+
 ions, triggering 
DAT movement into an inward facing occluded conformation. This conformational 
change is brought about as a result of changes in the core substrate binding TMDs. 
These conformational changes lead to the release of DA and Na
+
 ion from S1 and N1 
binding sites respectively which leads to the weakening of the affinity of Na
+
 ion for 
the N2 binding site causing its release. The presence of this unbound Na
+
 ion causes 
DAT to move into the inward open conformation, causing the transport of DA along 
with the ions into the pre-synaptic neuron. Presence of physiologically high Na
+
 ion 
concentration on the extracellular side, forces DAT to move again into the outward 
open conformation [3, 79-85]. These conformational changes for DAT states are very 
well studies in LeuT and dDAT [30, 31, 86]. Studying homologue amino acid residues 
and computational modeling between these DAT structures and mammalian DAT 
provides a greater understanding of the functional importance of specific amino acid 
residues within the transporter. The alternating access mechanism for DA transport is 
assisted by the interaction between various different amino acid residues. The 
extracellular facing H193, D206, H375 and E396 residues helps in coordinating the 
Zn
++
 ion binding, which stabilizes DAT in the Na
+ 
bound outward facing 
conformation. Along with these residues, D79 and Y335 play an important role in 
maintaining DA transport. Mutations at these residues affect DA binding at the S1 
binding site, DA uptake capacity and conformational equilibrium of DAT [75, 76, 87]. 
19 
 
Upon substrate binding, hDAT undergoes conformational changes, which leads to the 
formation of an extracellular gate. This gate is as a result of a salt bridge formed 
between R85 and D476 which are residues of TMD 1 and 8 respectively such that 
mutation at R85 causes complete loss of DAT function. The side chain of F320 also 
undergoes rotational isomerization so as to associate itself with Y156 forming an inner 
extracellular gate, a part of the occluded outward DAT structure. The closure of the 
extracellular gate is followed by the inward movement of TMD 1b and 6a segments. 
DAT undergoes further conformational changes making it move into an inward 
occluded structure, in which an intracellular gate is formed, as a result of a salt bridge 
between R60 and D436 which are residues located in the N-terminus close to 
cytoplasmic end of TMD 1 and at the cytoplasmic end of TMD 8 respectively. This 
salt bridge is stabilized by a cation-π interaction between R60 and Y335 residues.  
These gating residues are highly conserved in SLC6 neurotransmitter transporter and 
any mutation in these residues affects the conformational changes of the transporter 
[31, 34, 76, 88, 89]. Another important component that plays a pivoting role in 
maintaining DAT structure and function is the presence of cholesterol which helps in 
maintaining an outward facing conformation [30, 90]. 
DAT regulation and binding partners 
DAT is regulated by post-translational modifications and its binding partners. DAT 
phosphorylation in-vitro is regulated by various different kinases such as PKA, PKC, 
CaMKII, ERK, mitogen-activated protein kinase (MAPK) and c-Jun N-terminal 
kinase (JNK) which influence sub-cellular localization and DAT transport [38, 48, 51, 
91]. Phorbol ester-mediated PKC-stimulated DAT phosphorylation decreases DAT 
transport Vmax,, with long term PKC-stimulation driving DAT towards lysosomal 
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degradation reducting total DAT levels [46, 54, 56, 58, 61-63, 92]. PKC activated by 
PMA also increases DAT-mediated efflux, indicating either a direct role for DAT 
phosphorylation in efflux or attraction of interacting partners that facilitates efflux 
[93]. Truncation of N-terminal DAT leads to reduction in the PKC-stimulated 
phosphorylation without affecting DAT’s ability to undergo internalization [59, 60]. 
Phosphorylation stabilizes the interaction of DAT and its binding partner α-synuclein, 
which regulates DAT function and also causes DA efflux. While α-synuclein interacts 
with DAT at its C-terminal residues 597-620, another binding partner, 
calcium/calmodulin-dependent protein kinase II alpha subunit (CaMKIIα) interacts at 
residues 598-620 regulating DAT function [41, 94]. In-vitro studies have shown 
CaMKIIα regulating DAT phosphorylation at the N-terminus and also playing a role 
in amphetamine (AMPH)-mediated DA efflux. Inhibition of CaMKIIα or mutation of 
the N-terminal phosphorylation residues attenuates AMPH-mediated DA efflux [95]. 
In contrast to the function of PKC, which causes reduction on DA uptake, ERK-
activation leads to an increase in DA transport, indicating the bidirectional role of 
phosphorylation on DAT depending upon the kinases that acts on it and related 
signaling pathways [96-98]. Another important group of kinases are the MAPKs 
which are activated by both, PKC-dependent and independent mechanisms. D2 DA 
receptor-stimulation leads to an increase in DA transport capacity and activation of the 
MAPK cascade by increasing intracellular Ca
++
 ions and activating PKC. Inhibition of 
MAPK causes decrease in DA transport capacity and clathrin-dependent DAT 
redistribution from plasma membrane to cytosol [96, 99, 100].  
An important 10 residue sequence on DAT C-terminus is the FREKLAYAIA region 
which occupies residues 587-596. This sequence is highly conserved in other 
neurotransmitter transporters and is required for PKC regulated DAT internalization 
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and DAT trafficking. The neuronal GTPase Rin (Rit2) associates itself with 
FREKLAYAIA and DAT/Rin interaction enhances the PKC-stimulated DAT 
endocytosis, with mutations in the amino acid residues 589 and 590 causing reduction 
in DAT endocytosis [56, 73, 74].  
The DAT N-terminus also interacts with the soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE) protein, syntaxin 1A (syn 1A) and the receptor 
for activated C kinase (RACK1), both of which play a role in DAT trafficking 
regulated by PKC-activated phosphorylation. Syn 1A interacts with N-terminal 
residues 1-33 causing a reduction in DAT transport activity [41]. AMPH stimulates 
the interaction of DAT and syn 1A causing localization of syn 1A closer to DAT on 
the plasma membrane. This promotes DA efflux and localization of DAT into the 
membrane raft  microdomains [101].  
The membrane microdomain marker, Flotillin (flot1) is known to take part in clathrin-
mediated PKC-stimulated DAT endocytosis and modulate the association of DAT 
with cholesterol rich membrane raft microdomains causing a decrease in membrane 
mobility. Disruption of flot1 causes alterations in DAT structure, function and 
impairment of PKC- and CaMKII-dependent DAT regulation. Flot1 also regulates 
AMPH-mediated DA efflux such that its absence reduces the effect of AMPH [92, 
102-104].  
DA D2 receptors regulate DAT by direct interaction. This interaction is between 
residues 1-15 on the N-terminus of DAT and the intracellular loop 3 (IL3) of D2 
receptors. These interactions help recruit DAT to the plasma membrane and also 
increase DA uptake. The disruption of these interactions cause a decrease in DAT 
uptake capacity and locomotor activities (Fig. 9) [105].  
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Image courtesy, Vaughan, R.A. and Foster, J.D., Mechanisms of dopamine transporter 
regulation in normal and disease states. Trends Pharmacol Sci, 2013. 34(9): p. 489-
96, with permission [41]. 
Figure 9: DAT and its binding partners.  
DAT is a 12 TMD helical protein with its N- and C-termini facing towards the cytosol. 
These termini undergo post-translational modifications, such as phosphorylation and 
palmitoylation, and also interact with a large number of binding partners. These 
modifications and binding partners together play a regulatory role towards proper 
DAT function. 
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Reciprocal roles of phosphorylation and palmitoylation 
DAT has shown reciprocal roles for its post-translational modifications, 
phosphorylation and palmitoylation. Mutational and pharmacological studies 
demonstrate that these modifications are reciprocally regulated such that a pool of 
DAT upon being phosphorylated shows decrease palmitoylation levels and visa versa. 
While phosphorylation dictates DA transport capacity, DA efflux and DAT 
internalization, palmitoylation regulates DAT degradation and turnover. Although the 
actual mechanism for the reciprocal regulation of DAT in terms of phosphorylation 
and palmitoylation is not fully understood, it has been well studied in proteins such as 
β2-adrenergic receptors and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors, where steric hindrance between these modifications oppose each 
other [106-110]. With the three dimensional structure for mammalian DAT not 
known, one of the explanations for this reciprocal phosphorylation and palmitoylation 
status in DAT could be their distinct occurrences on the membrane microdomain with 
phosphorylation causing increased DAT distribution in the membrane raft 
microdomain and palmitoylation driving the membrane raft partitioning in proteins 
[30, 56, 110, 111]. Also palmitoylation could affect the rest of the downstream C-
terminus, which acts as a latch locking the transporter in the outward facing 
conformation, affecting the overall orientation of the active sites of DAT. Thus 
palmitoylation driven alteration could impact the interaction between the TMDs 
during DA transport, also affect DAT phosphorylation [10, 88, 110]. With 
phosphorylation and palmitoylation affecting various DAT properties such as 
membrane raft partitioning, lateral membrane mobility, surface expression and DA 
efflux, an impact on these modifications may cause dopaminergic imbalances that are 
associated with diseases such as ADHD, AD, PD, BPD and ASD [9, 110, 112-114]. 
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Psychostimulant drugs 
DAT is a primary target of many psychostimulant drugs such as methamphetamine 
(METH), AMPH and cocaine (COC). These drugs target DAT interfering with its 
function and expression disrupting dopaminergic homeostasis.  
COC is a NSS uptake blocker which competes with DA to bind at the substrate 
binding site. Once bound COC locks DAT in an outward facing conformation, 
restricting its ability to transport DA. This leads to accumulation of DA in the synapse 
causing euphoria, increased locomotion, hyperactivity, all caused as a result of 
activation of brain circuitry leading to stimulation of rewarding properties [115-119].  
AMPH is a substrate that is involved in providing reward and reinforcing properties. 
At high concentrations, AMPH is a substrate competing with DA to be transported 
into the pre-synaptic neuron, where it is able to move into the synaptic vesicles via 
vesicular monoamine transporter (VMAT). Within the vesicles, AMPH acts as a weak 
base disrupting the proton gradient, needed for neurotransmitter packaging. This 
causes release of DA from the vesicles into the cytoplasm eventually to be effluxed, 
affecting transporter Vmax and endocytosis. AMPH is also able to inhibit MAO or 
COMT which mediate DA oxidation and inactivation (Fig. 10) [3, 26, 40, 120-130]. 
Thus AMPH is able to disrupt DAT function and cause euphoria [129].  
AMPH activates PKC, ERK and CaMKII-stimulated DAT phosphorylation, which 
regulates DAT-mediated DA efflux with inhibition of these kinases significantly 
reducing the DA efflux [40, 127, 131-135]. The role of phosphorylation in AMPH-
mediated DA efflux is also evident by the fact that truncation of first 21 residues of the 
N-terminus or substituting the first 5 N-terminal Ser residues to Ala, leads to a 
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Image courtesy, Espana, R.A. and Jones, S.R., Presynaptic dopamine modulation by 
stimulant self-administration. Front Biosci (Schol Ed), 2013. 5: p. 261-76, with 
permission [119]. 
Figure 10: Action of COC and APMH on DAT. 
After the transmission of neurological signal via the post-synaptic neurons, DA is 
taken-up by DAT into the pre-synaptic neurons to be repackaged into synaptic 
vesicles. COC competes with DA to bind at the substrate binding site of DAT. Once 
bound, COC locks DAT in an outward facing conformation, preventing the uptake of 
DA. This leads to an increase in the amounts of DA in the synapse, which binds to the 
DA receptors on the post-synaptic neurons, triggering excessive downstream 
signaling. AMPH also competes with DA to bind at the substrate binding site, and is 
able to be transported via DAT into the pre-synaptic neurons. Once in the pre-synaptic 
neuron, AMPH disrupts the vesicular packaging of DA, leading to an increase in 
cytosolic levels of DA. This DA is effluxed via DAT into the synapse increasing the 
synaptic levels of DA. 
 
  
26 
 
decrease in APMH-stimulated DA efflux, without affecting DA uptake [136]. While 
PKC brings about phosphorylation by directly binding at the N-terminus, CaMKII 
binds at the C-terminus interacting with α-synuclein presumably bringing about N-
terminal phosphorylation. Upon phosphorylation, syn 1A interacts with N-terminal 
DAT stimulating AMPH-mediated DA efflux by shifting DAT towards a more efflux 
willing state (Fig. 11) [50, 137-140]. 
With the exact mechanism for AMPH-mediated DAT phosphorylation not fully clear, 
there could be many possibilities driving this phenomenon. AMPH could regulate the 
neuronal circuits or the neurotransmitter levels that are linked to signaling, causing a 
rise in phosphorylation. Also AMPH could affect the PKC sub-cellular localization, 
causing increase in phosphorylation within these regions. The uptake of AMPH into 
the pre-synaptic neuron causes an increase in the intracellular levels of Ca
++
, H
+
 or 
Na
+ 
ions which affects kinases and phosphatases, causing a rise in phosphorylation. 
Evidence suggests that there exists a rapid DA efflux process that occurs non-
traditionally, through a channel like mode of DAT. This mode is independent of the 
ion mediated DA efflux and is facilitated by Zn
++ 
ions (Fig. 12) [140-142].  
The inhibition of AKT upon the increase of AMPH-mediated CaMKII activity 
suggests the involvement of insulin signaling in DAT trafficking and DA homeostasis. 
This involvement is confirmed as the inhibition of insulin activated receptors cause a 
reduction in DA clearance due to the loss of DAT surface expression [140, 143, 144]. 
Also the inhibition of components of the insulin signaling pathway such as Akt and 
phosphatidylinositol 3-kinase (PI3K) cause a decrease in DA clearance and DAT 
surface expression with inhibition of PI3K causing reduction in AMPH-stimulated DA 
efflux [140, 145, 146]. 
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Image courtesy, Robertson, S.D., Matthies, H.J. and Galli, A., A closer look at 
amphetamine-induced reverse transport and trafficking of the dopamine and 
norepinephrine transporters. Mol Neurobiol, 2009. 39(2): p. 73-80, with permission 
[140]. 
Figure 11: AMPH induced DAT efflux regulated by second messengers. 
Transport of extracellular AMPH into the pre-synaptic neurons via DAT leads to 
increase in intracellular Ca
++ 
and Na
+ 
ions. This result in activation of kinases such as 
PKC and CAMKII that enhance DAT phosphorylation by interacting at the N- and C-
termini of DAT respectively promoting DAT mediated DA efflux. 
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Image courtesy, Robertson, S.D., Matthies, H.J. and Galli, A., A closer look at 
amphetamine-induced reverse transport and trafficking of the dopamine and 
norepinephrine transporters. Mol Neurobiol, 2009. 39(2): p. 73-80, with permission 
[140]. 
Figure 12: Schematic representation of transporter mediated monoamine efflux.  
DAT present in the inward facing conformation is able to mediate efflux by binding to 
substrate and co-transporter ions. Presence of AMPH and intracellular Na
+
 ions causes 
DAT to acquire inward facing conformation where it binds to DA causing increase in 
efflux. This alternating access mechanism driven efflux is a slow exchange mechanism 
of efflux. AMPH is also able to induce a rapid efflux through a channel like mode of 
DAT which is facilitated by Zn
++ 
ions upon AMPH-stimulation. 
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DAT and diseases 
Abnormalities or dysfunctions in DA homeostasis cause dopaminergic imbalances 
which are associated with neurological and neuropsychiatric diseases [147, 148]. 
Various DAT abnormalities occur as a result of nucleotide polymorphism seen in its 
coding and/or non-coding gene sequences [149].   
PD 
PD is a progressive disorder characterized with loss of dopaminergic neurons in the 
SNc region of the brain leading to low levels of DA in the brain. There are two  
familial forms of PD, that are caused either by mutation or by over-expression of α-
synuclein and Parkin, both of which affect the regulatory aspect of DAT [41]. α-
synuclein is a DAT interacting scaffolding protein whose actual role in PD is poorly 
understood. It interacts with C-terminal DAT regulating the recruitment of DAT on 
the plasma membrane [150, 151]. It also plays a role in SNc degradation causing DA-
induced apoptosis [151]. Parkin, an E3 ubiquitin ligase, regulates ubiquitylation and 
degradation of DAT. Mutation in this protein leads to prevention of misfolded or 
unwanted DAT from being degraded. Thus the accumulation of the misfolded DAT 
leads to its oligomerization with properly folded DAT preventing it from travelling to 
the plasma membrane. This leads to decrease in DA uptake [41, 65, 152, 153]. 
Angelman syndrome 
Angelman syndrome is a neurological disorder which occurs as a result of a defective 
maternal inherited allele of the E3 ubiquitin ligase that leads to the reduction of 
CaMKII activity. This is brought about by increased inhibitory auto-phosphorylation 
[10, 41]. A mouse model for Angelman syndrome showed the accumulation of auto-
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inhibited αCamKII in the brain causing characteristics such as suppressed AMPH 
induced efflux. The mouse model also showed a decrease in synaptic DA levels, 
which was similar to PD like phenotype [154, 155].   
ADHD 
ADHD is a neurological disorder having symptoms including hyperactivity, attention 
difficulty, impulsiveness and motor impairment [156]. ADHD affects 3-6% of children 
worldwide with symptoms continuing in adulthood in 5-6% of these cases, with a 
worldwide prevalence rate of ADHD being 5-7%. ADHD also has an estimated 
heritability rate of 0.7-0.9% with a large genetic variation among the individuals 
suffering from ADHD [157-160]. It has been hypothesized that ADHD characteristics 
arise as a result of impaired dopaminergic transmission and excess DA uptake [26, 
130, 161]. Various SNPs in hDAT, V55A, R237E, I312F, V382A, R421N, A559V, 
E602G and R615C, have been identified in patients diagnosed with ADHD and/or 
bipolar disorder as well as few non diagnosed individuals [7, 18, 41, 114, 162-165]. 
These SNPs are located at different positions on DAT structure and play an important 
role in the proper expression and function of DAT. 
V55A and V382A, located in the N-terminal and extracellular loop 4 (EL4) 
respectively, show a reduced DAT surface expression and a decreased DA transport 
capacity with V382A also destabilizing the extracellular gate [18, 166]. R421N has a 
compromised N2 binding site along with a large cation leak and DA efflux while 
I312F has a reduced DA transport capacity [114]. R615C, located at the αCaMKII 
binding site on the C-terminus, shows increased phosphorylation and a greater DAT 
membrane raft microdomain localization. It also displays a constitutive level of DAT 
endocytosis and recycling, with a greater lateral mobility insensitive to AMPH. This 
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mutant is insensitivity to PKC-stimulated DAT trafficking and maintains AMPH-
mediated DA efflux, with a decrease in DAT surface expression, DA transport Vmax. 
R615 is phosphorylated and forms a phosphorylation site motif with T613 [9, 41, 113, 
167, 168]. Not much is known about R237E and E602G. 
A559V is located on the extracellular end of TMD 12, and was first identified in two 
male siblings with ADHD. This mutant displays anomalous DA efflux (ADE) (reverse 
transport) with individuals showing signs of motor dysfunction. A559V displays 
reduction in ADE upon AMPH-stimulation with resistance to APMH-mediated DAT 
cell surface distribution and normal levels of DA uptake. Recently, A559V was found 
in patients with autism spectrum disorder (ASD) and this mutant displayed impaired 
AMPH transport to the intracellular side of DAT and also failed to incur cell surface 
loss of DAT. In case of ASD patients, inhibition of PKC restored the AMPH-induced 
DAT trafficking and intracellular AMPH accumulation.  
The diminished ability of A559V to transport AMPH via DAT into the pre-synaptic 
neuron could be as a result of the bulkier Val substitution. Also, since A559V has 
elevated D2 receptor signaling, application of D2 receptor blocker inhibits the ADE, 
thus indicating that increased signaling could play a role in the elevated PKC activity. 
Thus, N-terminal phosphorylation which promotes D2 receptor signaling through PKC 
could bring about DA dysfunction in ADHD and ASD individuals [7-9, 26, 30, 95, 
114, 136, 164, 169-171]. 
Another DAT mutant associated with ASD is T356M. This mutant displays AMPH 
insensitive ADE, as seen in A559V hDAT, along with reduced DA uptake capacity 
despite having a normal surface expression [26, 77, 113]. 
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DAT association with lipid rafts and lateral membrane mobility 
DAT is associated with cholesterol-rich membrane raft microdomains [56, 172, 173]. 
Membrane cholesterol is important for proper DAT function and it favors an outward 
facing conformation for DAT [90]. The depletion of cholesterol disrupts the 
membrane rafts microdomains which abolishes PKC-stimulated DAT down 
regulation, decreases DA transport activity and DAT surface expression [173]. 
Techniques like Fluorescence Recovery After Photobleaching (FRAP) and 
Fluorescence Correlation Spectroscopy (FCS) have shown that cholesterol affects 
lateral membrane mobility, such that disruption of cholesterol or cytoskeleton 
increases the mobility [172].  
Membrane rafts are diverse, dynamic membrane microdomains that are rich in 
cholesterol and glycosphingolipids. Membrane rafts are associated with various 
cellular processes such as signal transduction, protein sorting and membrane 
trafficking. DAT is distributed between membrane raft and non-raft regions, with 
membrane rafts playing a role in compartmentalization of DAT affecting 
dopaminergic neuronal activity [41, 56, 174-176]. Evidence suggests DAT localized in 
membrane rafts microdomain have a lower DA binding potency and a reduced rate of 
DA clearance while DAT localized in membrane non-rafts microdomain have a 
greater DA binding potency and a greater DA clearance. Membrane rafts and non-rafts 
microdomains behave differently in their phosphorylation properties. PKC-mediated 
phosphorylated DAT is seen to be enriched in membrane rafts regions indicating that 
membrane rafts may serve as a platform for PKC-stimulated DA efflux. DAT 
internalization is seen to occur in membrane non-raft microdomain. Inappropriate 
localization of DAT within raft and non-raft microdomains adversely affects its  
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function [56, 136, 140].  
The interaction of flot1 with DAT affects its lateral membrane mobility. Flot1 is 
important for proper membrane raft distribution and its presence reduces DAT lateral 
membrane mobility [92, 102]. Presence of flot1 causes retention of DAT on the cell 
surface mediating DA efflux [113, 177]. DAT is associated with cytoskeletal and lipid 
elements, which reduces its lateral membrane mobility. Disruption of these elements 
increase DAT mobility. This lateral membrane mobility is also affected by membrane 
raft microdomains, the disruption of which causes a decrease in DAT function, Vmax 
and Km for DA [172].  
DHHC palmitoyl transferases enzymes 
S-palmitoylation is regulated by a large family of Asp-His-His-Cys (DHHC) enzymes 
which are palmitoyl acyltransferases (PAT). These enzymes palmitoylate large groups 
of proteins, among which DHHC2, 3, 7 and 15 are the most active. These DHHC 
enzymes are proteins with Cys rich domains (CRD) and a consensus signaling 
sequence of Asp-His-His-Cys residues, which are highly conserved from yeast to 
mammals (Fig.13) [178, 179]. Mammalian cells have a total of 23 DHHC enzymes, all 
of them containing 4-6 TMDs [179-182]. Most of these DHHC enzymes are 
associated with the golgi complex or endoplasmic reticulum (ER) but DHHC2 is 
localized within the dendritic vesicles of neurons and DHHC5, 20 and 21 are localized 
on the plasma membrane. DHHC2 is seen to cycle between the plasma membrane and 
endosomes with the C-terminus of DHHC2 playing a role in its membrane trafficking 
[72, 182-186]. Mutations in DHHC enzymes are associated with large number 
neurological disorders. Mutation of DHHC3 is associated with behavioral 
abnormalities. Microdeletions and SNPs within the DHHC8 gene is associated with 
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increased risk of schizophrenia. Mutations in DHHC15 and DHHC9 are associated 
with X-linked mental retardation [181, 187-190].   
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Image courtesy, Greaves, J. and Chamberlain, L.H., DHHC palmitoyl transferases: 
substrate interactions and (patho)physiology. Trends Biochem Sci, 2011. 36(5): p. 
245-53, with permission [190]. 
Figure 13: Membrane topology of DHHC proteins and its aligned sequences.  
The DHHC proteins have 4-6 TMDs with its N- and C-termini facing toward the 
cytosol. The sequence alignment and consensus of 24 different mouse DHHC proteins, 
with amino acids residues 29-32 having a consensus sequence except for DHHC13 
that has Gln at residue 30.  
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CHAPTER II 
ADHD ASSOCIATED DOPAMINE TRANSPORTER MUTANT, A559V HAS 
ALTERED, RECIPROCAL PHOSPHORYLATION AND PALMITOYLATION 
STATUS  
ABSTRACT 
The dopaminergic system plays a role in controlling motor, cognitive and behavioral 
activities with the neurotransmitter dopamine (DA) modulating brain circuits 
involving mood, reward, sleep patterns and locomotion and the dopamine transporter 
(DAT; SLC6) maintaining DA homeostasis. DAT is a target for psychostimulant 
substrates such as amphetamine (AMPH) and psychostimulant uptake blockers such as 
cocaine (COC), both disrupting DAT function, impacting DA uptake with AMPH 
causing DA efflux. An attention-deficit hyperactivity disorder (ADHD) associated 
single nucleotide polymorphism (SNP) in human DAT (hDAT), A559V hDAT, 
displays anomalous DA efflux (ADE), with DA uptake, total and surface expression 
levels being similar to wildtype (WT). Here we investigate the phosphorylation and 
palmitoylation status for A559V and its rat homologue, A558V rat DAT (rDAT) using 
metabolic labeling and acyl-biotinyl exchange (ABE) respectively. We demonstrate 
that A559V and A558V display AMPH independent elevated phosphorylation, which 
in WT causes DA efflux and N-terminal phosphorylation, and decreased 
palmitoylation respectively. We also demonstrated that A558V rDAT displayed 
AMPH independent increased T53 phosphorylation. This increased phosphorylation 
may contribute to ADE seen for this polymorphism. We also showed C581 to be a 
palmitoylation site in hDAT and that the palmitoylation deficient C581A hDAT 
mutant displays enhanced basal and PMA stimulated phosphorylation consistent with 
reciprocal regulation of these modification as recently reported.  
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Palmitoylation studies on phosphorylation deficient mutants, T53A rDAT, S7A hDAT 
and S53A hDAT (human homologue for T53A rDAT) displayed increased 
palmitoylation, providing further evidence of the reciprocal nature of these post-
translational modifications. 
For A559V hDAT, we believe that the bulkier Val substitution in place of Ala at 
residue 559 may mechanistically hinder palmitoylation at C581, which could be the 
driving force for reciprocal N-terminal phosphorylation. This increased 
phosphorylation is associated with DA efflux as seen by AMPH-stimulation or by this 
polymorphism (A559V). T53A rDAT, S7A hDAT and S53A hDAT must be harboring 
similarly targeted phenomenon to bring about the reciprocal post-translational 
modifications.  
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INTRODUCTION 
The Dopamine transporter (DAT) is a 12 transmembrane spanning domain (TMD) 
helical structure belonging to the solute carrier 6 (SLC6) gene family which plays a 
critical role in maintaining and coordinating dopamine (DA) mediated signaling in the 
central nervous system (CNS) [2-6, 9, 11, 12, 14, 15].  
Present on pre-synaptic neurons, DAT maintains the dynamics of DA 
neurotransmission by actively transporting extracellular DA from the synapses into the 
pre-synaptic neurons. This transport is highly regulated by many signaling pathways 
and post-translational modifications. DAT regulated DA homeostasis, prevents over 
stimulation of the post-synaptic receptors and also helps recycle DA for future 
neurotransmission [3, 110, 191]. Several neurological diseases such as schizophrenia, 
bipolar disorder (BPD), Parkinson’s disease (PD), attention-deficit hyperactivity 
disorder (ADHD), autism spectrum disorder (ASD) and mood disorders such as 
depression, anxiety and obsessive compulsive disorder (OCD) are associated with 
abnormal DA homeostasis and/or polymorphisms in DAT, although the role of DAT 
dysfunction in these diseases is not clearly understood [6-10, 17-21, 26, 41, 112, 192].  
DAT is a target for various addictive and therapeutic drugs that either act as uptake 
blockers, such as cocaine (COC), or act as substrates, such as amphetamine (AMPH), 
which stimulates DA efflux (reverse transport). In either of these cases there is an 
accumulation of DA in the synaptic space [191]. AMPH disrupts DAT function by 
affecting DA uptake, DAT surface expression and endocytosis. AMPH upon binding
39 
 
at the substrate binding site is transported into the pre-synaptic neuron. Here it moves 
into the synaptic vesicles via vesicular monoamine transporter (VMAT). Being a weak 
base, accumulation of AMPH disrupts the proton gradient causing DA release from 
the synaptic vesicle which is then effluxed [3, 26, 40, 120-130]. This AMPH triggered 
DA efflux is driven by N-terminal DAT phosphorylation stimulated by protein kinases 
and proline directed kinases [57, 110].  
DAT undergoes phosphorylation and palmitoylation, which play a regulatory role in 
DAT function. In-vitro studies have identified DAT to be phosphorylated on the N-
terminus at residues S4, 7, 13 and T53 for rat DAT (rDAT) and S7, 13 for human 
DAT (hDAT) with phosphorylation causing DA efflux, down-regulation of DAT, 
reduction in DAT surface expression and Vmax [9, 39-41, 48-54, 56, 62, 63, 91]. DAT 
is S-palmitoylated, a reversible addition of a saturated fatty acid moiety (palmitate) via 
a thioester bond, on its C-terminus at C580 in rDAT, with one or more palmitoylation 
sites currently unknown [36, 64]. Palmitoylation affects DAT transport kinetics, 
turnover, degradation and protein kinase-stimulated down regulation [36, 72]. DAT is 
reciprocally regulated for these two post-translational modifications [110].  
A large number of DAT dysfunction occurs as a result of single nucleotide 
polymorphism (SNP), seen in its coding as well as non-coding gene sequences. Many 
of which are identified in patients diagnosed with neurological disorders. SNPs 
identified in hDAT are V55A, R237E, V382A, A559V, R615C, I312F and R421N [7, 
18, 41, 114, 162-165]. The A559V hDAT mutant has been recently reported in several 
independent cases as well as individuals diagnosed with ADHD, ASD or BPD [9, 162, 
164, 169]. Studies have shown that although A559V hDAT shows DA uptake, total 
and surface DAT expression similar to wildtype (WT), it displays anomalous DA 
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efflux (ADE). This mutant also showed resistance to AMPH-stimulated cell surface 
redistribution and a reduction in DA efflux [8, 9, 18, 193]. In patients suffering from 
ASD, A559V hDAT mutant displayed impaired AMPH transport via DAT. This 
mutant failed to incur cell surface loss of DAT and inhibition of PKC-mediated 
phosphorylation [169].  
Since A559V hDAT displays ADE, a phenomenon associated with AMPH-mediated 
phosphorylation in WT, we investigated the phosphorylation status of this mutant 
along with its rat homologue, A558V rDAT, including T53, a proline directed 
phosphorylation site, specific for rDAT. With recent findings that DAT is reciprocally 
regulated for these post-translational modifications, we examine the palmitoylation 
status for A559V hDAT and A558V rDAT. We also investigate phosphorylation 
deficient mutants, T53A rDAT, S7A rDAT and S53A rDAT for palmitoylation levels 
in order to study their response to loss of specific phosphorylation sites. With C580 
identified as a palmitoylation site in rDAT, we also investigate C581 (human 
equivalent being C580) for its palmitoylation status. Here we present insights on the 
increased phosphorylation status for A559V, which is associated with ADE, and its 
reciprocal nature in palmitoylation, along with site specific phosphorylation mutants in 
hDAT. 
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EXPERIMENTAL METHODS 
Cell culture and site directed mutagenesis 
Lewis lung carcinoma-porcine kidney (LLC-PK1) cells were transfected and selected 
to stably express WT DAT: hDAT and rDAT; mutant DAT: S7A hDAT, S53A hDAT, 
A559V hDAT, C581A hDAT, A558V rDAT and previously characterized T53A 
rDAT and C580A rDAT [36, 38, 49]. The codon substitutions were generated using 
the Stratagene QuikChange® Kit, with WT, hDAT or rDAT, pcDNA 3.0 plasmids as 
the template. Mutations were verified by sequencing (Eurofins MWG). LLC-PK1 cells 
were grown in 12-well culture plates and were transfected with 1.4 μg plasmid/well 
and XtremeGene transfection reagent. Transformants were selected 24-48 hours later 
by adding 800 μg/mL geneticin (G418 sulfate) to the culture medium. Transfected 
LLC-PK1 cells were maintained in α-minimum essential medium (AMEM) 
supplemented with 2 mM L-glutamine, 5% fetal bovine serum (FBS), 200 μg/mL 
G418 sulfate and 1X penicillin/streptomycin. Cells were grown in an incubation 
chamber gassed with 5% CO2 at 37°C. DAT expression level in transfected cells was 
verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and immunoblotting of the cellular lysates against DAT specific antibodies. 
Acyl-biotinyl exchange (ABE) 
Measurement of DAT palmitoylation was performed as described previously [36, 
194]. Cell membranes [~100 μg protein] pellet expressing WT or mutant DAT were 
solubilized in 200 μL lysis buffer (50 mM HEPES, pH 7.0, 2% SDS, 1 mM
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ethylenediaminetetraacetic acid (EDTA)) containing protease inhibitors and 20 mM 
methyl methanethiosulfonate (MMTS) with end-over-end mixing for 1 hour at room 
temperature (RT). The excess MMTS was removed by 3 sequential 1 mL acetone 
precipitations followed by vortexing and centrifugation at 16,000 X g for 10 minutes 
at RT. Pelleted protein was solubilized in lysis buffer containing MMTS and protease 
inhibitor and incubated overnight at RT with end-over-end mixing. 
The next day, following the removal of excess MMTS by 3 sequential acetone 1 mL 
precipitations, the precipitated protein pellet was re-suspended in 300 μL 4SB buffer 
(4% SDS, 50 mM tris-HCl, 5 mM EDTA, pH 7.4). The solubilized pellet was divided 
into two equal portions and one was treated with 50 mM tris-HCl (pH 7.4) while the 
other was treated with 0.7 M hydroxylamine (NH2OH) (pH 7.4) with end-over-end 
mixing for 2 hours at RT. Excess hydroxylamine was removed by 3 sequential 1 mL 
acetone precipitations and the precipitated protein pellet was re-suspended in 240 μL 
4SB buffer and biotinylated by adding 900 μL of 50 mM tris-HCl (pH 7.4) containing 
0.4 mM sulfhydryl-reactive N-(6-(biotinamido)hexyl)-3′-(2′-pyridyldithio)-
propionamide (HPDP-biotin) with end-over-end mixing for 1 hour at RT. Following 
the removal of the unreacted HPDP-biotin by 3 sequential acetone 1 mL 
precipitations, the final protein pellet was solubilized in 150 μL lysis buffer. 10 μL 
aliquots of ABE lysates were immunoblotted for DAT expression levels. ABE lysates 
were adjusted to contain equal amounts of total DAT protein and 0.1% SDS with lysis 
buffer and 50 mM tris-HCl (pH 7.4) respectively. Biotinylated proteins were extracted 
by incubating the ABE lysates with 25 μL neutrAvidin resin with end-over-end mixing 
overnight at 4°C. The next day, the resin was washed thrice with 800 μL 
RadioImmunoPrecipitation Assay (RIPA) buffer (1% triton X-100, 1% sodium 
deoxycholate, 1% SDS, 125 mM sodium phosphate, 150 mM sodium chloride, 2 mM 
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EDTA, 50 mM sodium fluoride) and palmitoylated proteins were eluted with 32 μL 
2X laemmli sample buffer containing 5% 2-mercaptoethanol. Following an incubation 
of elute for 20 minutes at RT, they were subjected to SDS-PAGE and immunoblotting 
for DAT using DAT specific antibody against C-terminus of hDAT or N-terminus of 
rDAT. In all experiments the level of signal intensity from Tris-HCl controls was less 
than 5% of NH2OH treated samples. Experiments were independently performed three 
or more times and results are reported as mean ± standard error. Statistical analyses 
were done by unpaired Student’s t-test using graphpad prism software. 
Cell membrane preparation 
Cells expressing WT or mutant DAT were grown in 150 mm culture plates until ~80% 
confluent. After a quick wash with ice cold buffer B (0.25 M sucrose, 10 mM 
triethanolamine, 10 mM acetic acid, pH 7.8), cells were scraped using 1 mL buffer B 
containing protease inhibitors. The cells were collected and centrifuged at 3,000 X g 
for 5 minutes at 4°C followed by transfer of the pellet in 1 mL buffer C (0.25 M 
sucrose, 10 mM triethanolamine, 10 mM acetic acid, 1 mM EDTA, pH 7.8) containing 
protease inhibitor to a Dounce homogenizer. Cells were homogenized using 30 up and 
down strokes and cellular lysates were centrifuged at 800 X g for 10 minutes followed 
by centrifugation of the supernatant fraction again at 16,000 X g for 12 minutes. The 
resulting pellet containing the cell membranes was suspended in 1 mL SP buffer (0.32 
M sucrose, 10 mM sodium phosphate, pH 7.4) containing protease inhibitor and 
assayed for protein content using BCA protein assay method. 
DAT T53 phosphorylation assay 
Cells expressing WT or mutant DAT were grown in 6-well culture plates until ~80%  
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confluent. After a quick wash with ice cold Kreb’s-Ringer HEPES (KRH) buffer (25 
mM HEPES, 125 mM sodium chloride, 1.3 mM calcium chloride, 4.8 mM potassium 
chloride, 1.2 mM potassium dihydrogen phosphate, 1.2 mM magnesium sulfate, 5.6 
mM glucose, pH 7.4) cells were treated with vehicle or 10 μM AMPH in KRH for 20 
minutes at 37°C. Following washes with ice-cold KRH, the cells were solubilized with 
200 μL RIPA containing protease inhibitors with continuous rocking for 30 minutes. 
Cellular lysates were adjusted to contain equal amounts of total DAT protein using 
RIPA and pT53
 
DAT was immunoprecipitated using phospho-specific antibody 
against T53 DAT followed by SDS-PAGE and immunoblotting for DAT using DAT 
specific antibody against N-terminus of rDAT. Experiments were independently 
performed three or more times and results are reported as mean ± standard error. 
Statistical analyses were done by unpaired Student’s t-test using graphpad prism 
software. 
Metabolic [32]PO4-
 
labeling 
Metabolic 
32
PO4 labeling in cells expressing WT or mutant DAT was performed as 
previously described [40]. Cells were grown in 6-well culture plates until ~80% 
confluent after which they were incubated with phosphate free medium for 1 hour 
prior to labeling with the same medium containing 0.5 mCi/mL 
32
PO4 for 2 hours at 
37°C. Following metabolic labeling, cells were treated with vehicle or 10 μM AMPH 
for 20 minutes at 37°C after which they were washed with ice-cold Buffer B before 
being scrapped in 500 μL buffer B. The cellular lysates were centrifugated at 2,000 x g 
for 5 min at 4 °C, and the cell pellet was suspended in 700 μL lysis buffer (10 mM 
triethanolamine/acetate buffer, pH 7.8, 2 mM EDTA, 150 mM sodium chloride, 15% 
sucrose, 0.1% triton X-100, 100 mM dithiothreitol (DTT)) containing protease 
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inhibitors followed by end-over-end mixing for 10 minutes at 4°C. The lysates were 
then centrifuged at 4,000 X g for 5 minutes at 4°C and the resulting supernatant was 
transferred, adjusted to contain 0.5% SDS and mixed. Following centrifugation at 
20,000 X g for 30 minutes at 4°C, the final supernatant was collected for DAT 
immunoprecipitation. Cellular lysates were adjusted to contain equal amounts of total 
DAT protein using lysis buffer and 
32
P-DAT was immunoprecipitated using DAT 
specific antibody against C-terminus of hDAT or N-terminus of rDAT followed by 
SDS-PAGE. Gels were vacuum dried for 2 hours at 72°C followed by exposure to X-
Ray film to detect 
32
P-DAT. The autoradiograms were developed and quantified using 
Quantity-1.0® analysis software. Experiments were independently performed three or 
more times and results are reported as mean ± standard error. Statistical analyses were 
done by unpaired Student’s t-test using graphpad prism software.  
Crosslinking immunoglobulin (IgG) to protein-A sepharose beads 
Protein-A sepharose beads (0.4 gms) were hydrated with 0.2 M triethanolamine (pH 
8.0) for 15 minutes with mixing every 5 minutes. The hydrated beads were washed 
thrice with 5 mL 0.2 M triethanolamine followed by a quick vortex and centrifugation 
at 1,000 X g for 2 minutes. After the third centrifugation the hydrated protein-A 
sepharose beads were incubated for 45 minutes at RT with primary antibody (Table 1) 
diluted in 10 mL of 0.2 M triethanolamine with end-over-end mixing. The incubated 
protein-A sepharose beads were washed twice with 5 mL 0.2 M triethanolamine and 
centrifuged at 1000 X g for 2 minutes. Following washes, the beads were incubated 
with dimethyl pimelimidate (DMP) mix (65 mg DMP/13 mL 0.2 M triethanolamine) 
for 45 minutes at RT with end-over-end mixing. The beads were then washed twice 
with 100 mM tris-HCl (pH 8.0) and finally with ImmunoPrecipitation (IPB) Buffer  
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Table 1. The volume of specific antibodies required for crosslinking with the protein-
A beads based on the specificity of the antibodies.  
Primary Antibody Volume (μL) 
DAT specific goat polyclonal antibody raised against amino 
acids 601 to 620 of the C-terminus of human DAT (Santa Cruz 
Biotechnology) 
400 μL 
DAT specific mouse monoclonal antibody raised against 
synthetic peptide 16 containing amino acids 42 to 59 of the N-
terminus of rat DAT (Cell Essentials) 
200 μL 
DAT specific rabbit polyclonal antibody raised against 
phosphorylated T53 of the N-terminus of rat DAT (Arigobio) 
120 μL 
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 (50 mM tris-HCl, pH 8.0, 0.1% triton X-100) followed by being suspended and stored 
in 7-10 mL IPB containing 0.05% sodium azide at 4°C. 
Immunoprecipitation 
Cellular lysates containing equal amounts of total DAT protein were incubated with 50 
μL of a 50% slurry of protein sepharose-A beads crossed-linked to the desired primary 
antibody and 450 μL IPB and incubated overnight with end-over-end mixing at 4°C. 
The next day, DAT bound, primary antibody cross-linked sepharose-A beads were 
washed thrice with 800 μL IPB containing 0.1% SDS followed by a quick vortex and 
centrifuged at 8,000 X g for 2 minutes. Immunoprecipitated proteins were eluted with 
32 μL 2X laemmli sample buffer containing 5% 2-mercaptoethanol and subjected to 
SDS-PAGE and either immunoblotting for DAT or gels were dried for X-Ray film 
exposure.  
Immunoblotting 
Lysates were mixed with concentrated laemmli sample buffer containing 5% 2-
mercaptoethanol and subjected to SDS-PAGE using 4-20% tris/glycine-
polyacrylamide gels. Proteins were resolved by electrophoresis (150 Volts for 1.45 
hours) in 1X tris-glycine running buffer. The proteins were transferred to 0.2 μm 
polyvinylidene difluoride (PVDF) membranes (35 Volts for 1.45 hours) in 1X transfer 
buffer (25 mM tris, 192 mM glycine, 0.1% SDS, 20% methanol) at 4°C. Membranes 
were blocked overnight by incubation with 3% bovine serum albumin 
(BSA]/phosphate buffer saline (PBS; 1.37 M sodium chloride, 2.7 mM potassium 
chloride, 100 mM disodium phosphate, 18 mM potassium dihydrogen phosphate, pH 
7.4) at 4°C. Blocked membranes were probed for 1 hour at RT with DAT specific goat 
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polyclonal antibody raised against amino acids 601 to 620 of the C-terminus of hDAT 
or DAT specific mouse monoclonal antibody raised against synthetic peptide 16 
containing amino acids 42 to 59 of the N-terminus of rDAT (1:1000 dilution in 3% 
BSA/PBS). The bound antibodies were detected by incubating the PVDF membranes 
for 1 hour at RT with anti-goat or anti-mouse IgG 2° antibody linked to alkaline 
phosphatase (1:5000 dilution in 3% BSA/PBS), with 5 washes of 0.1% tween-20/PBS 
after each antibody treatment followed by incubation of the membranes with 3 ml 
alkaline phosphatase substrate for 5 minutes. The membranes were sandwiched 
between plastic film and imaged on a BioRad Image Doc System and quantified using 
Quantity-1.0® analysis software.  
Equipment 
Transfected LLC-PK1 cells were maintained in a Nuair 2700-30 water jacketed CO2 
incubator and handled in a Nuair class II type A/B3 class II biological safety cabinet 
laminar flow hood. Mutagenesis via PCR was performed using a thermocycler from 
Eppendorf.  
The cellular lysates were centrifuged using a Beckman Coulter
TM
 Microfuge® 16 or 
Microfuge® 22R microcentrifuge. The protein-A sepharose beads were centrifuged 
using Beckman Coulter
TM
 J6-M1 swing bucket ultracentrifuge. Cellular pellets were 
solubilized using a Bransonic® water bath sonicator.  
Cell membranes were assayed for protein content using Molecular Devices microplate 
reader.  
SDS-PAGE and protein transfer to PVDF membranes was performed using an XCell 
SureLock
TM 
electrophoresis apparatus and an XCell II
TM
 Blot module electrophoresis 
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transfer cell respectively from Invitrogen. The power supply used to control both the 
electrophoresis apparatus and electrophoresis transfer cell was also from Invitrogen. 
Gels were dried using a Bio-Rad Hydro vacuum gel drier. Illuminescence from PVDF 
membranes and autoradiograms were imaged using a Bio-Rad gel documentation 
system and analyzed using Bio-Rad Quantity-1.0® software. All statistical analyses 
were done using graphpad prism software.  
Materials 
AMEM, G418 sulfate, 1X Penicillin/Streptomycin, and L-Glutamine were from 
Corning Cellgro (Manassas, VA, USA); FBS was from Atlanta Biologicals (Atlanta, 
GA, USA); XtremeGene Transfection Reagent was from Roche (Indianapolis, IN, 
USA); Magnesium Sulfate, Glucose, AMPH, DMP, Sodium Azide, Colorburst 
Molecular Mass Standard Markers and anti-mouse IgG 2° antibody linked to alkaline 
phosphatase were from Sigma Aldrich (St. Louis, MO, USA); DAT specific goat 
polyclonal antibody raised against amino acids 601 to 620 of the C-terminus of hDAT 
and anti-goat IgG 2° antibody linked to alkaline phosphatase were from Santa Cruz 
Biotechnology (Dallas, TX, US); Triethanolamine and Hydroxylamine were from 
Acros Organics (New Jersey, USA); Dimethyl Sulfoxide (DMSO), Sucrose, HEPES, 
EDTA, Protease Inhibitor Tablets, Tween-20, Triton X-100, Acetic Acid, Sodium 
Deoxycholate, Sodium Chloride, Sodium Fluoride, BSA, Sodium Phosphate, 
Potassium Chloride, Disodium Phosphate, Calcium Chloride, Potassium Dihydrogen 
Phosphate, SDS, Methanol, Acetone, Glycine, 2-Mercaptoethanol, Tris-HCl, DTT, 
NeutrAvidin beads, MMTS and PVDF membranes were from Fisher Scientific 
(Waltham, MA, USA); 4-20% tris/glycine-polyacrylamide gels were from Lonza 
(Walkerville, MD, USA); Protein Sepharose-A beads was from GE Healthcare 
50 
 
Lifesciences (Piscataway, NJ, USA); HPDP-Biotin was from ProteoChem (Loves 
Park, IL, USA); DAT specific rabbit polyclonal antibody raised against 
phosphorylated T53 (pT53Ab) of the N-terminus of rat DAT was from 
PhosphoSolutions (Aurora, CO, USA); DAT specific mouse monoclonal antibody 
raised against synthetic peptide 16 containing amino acids 42 to 59 of the N-terminus 
of rDAT was from Cell Essentials (Boston, MA, USA); 
32
PO4 was from MP 
Biomedicals (Santa Ana, CA, USA) or Perkin Elmer (Waltham, MA, USA); Alkaline 
phosphatase substrate (ImmunStar) was from Bio-Rad (Hercules, CA, USA); X-Ray 
film was from GE Healthcare (Chicago, IL, USA). 
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RESULTS 
ADHD associated SNP, A559V hDAT and its rat homologue, A558V rDAT, display 
increased phosphorylation 
DAT phosphorylation is stimulated by protein kinases and proline directed kinases 
such as protein kinase C (PKC) and extracellular signal regulated pathway (ERK) 
respectively [40, 41, 49, 93, 95]. This phosphorylation is specific to the N-terminus 
such that truncation of the first 21 amino acid residues leads to significant reduction in 
phosphorylation levels. Drugs such as AMPH and PKC activators such as phorbol 12-
myistate, 13-acetate (PMA) stimulate these kinases causing elevation of DAT 
phosphorylation which plays a role in DA efflux and DAT endocytosis [40, 49, 57, 
129, 136, 140, 169, 195, 196]. 
First identified in two male siblings, ADHD associated SNP, A559V hDAT showed 
~300% increase in basal ADE, independent of AMPH-mediated stimulation, and that 
AMPH stimulation blocked this efflux [8, 9, 169]. Since phosphorylation of DAT is 
critical for ADE, we examined the phosphorylation levels of A559V hDAT along with 
C581A hDAT, homologue for palmitoylation deficient mutant C580A rDAT which 
previously was shown to have increased phosphorylation levels [9, 36, 110]. LLC-PK1 
cells stably expressing WT, A559V hDAT or C581A hDAT were labeled with 0.5 
mCi/mL 
32
PO4 and treated with vehicle or 10 μM AMPH. Equal amounts of DAT 
were immunoprecipitated for DAT and analyzed by SDS-PAGE/autoradiography (Fig. 
14). WT DAT displayed  typical level of phosphorylation with AMPH-mediated PKC-
stimulation causing an increase in phosphorylation levels over basal (138 + 8% of WT 
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Figure 14: A559V hDAT, C581A hDAT and their rat homologues display increased 
basal phosphorylation levels. 
LLC-PK1 cells stably expressing the indicated hDAT or rDAT forms were labeled in 
parallel with 0.5 mCi/mL 
32
PO4 and treated with vehicle or 10 μM AMPH. Equal 
amounts of DAT determined by immunoblotting (IB) were immunoprecipitated for 
DAT specific antibody against C-terminus of hDAT or N-terminus of rDAT and 
subjected to SDS-PAGE/autoradiography.  
Upper panels show representative autoradiograms and matching total DAT 
immunoblots. Vertical white dividing lines indicate the rearrangement of lanes from 
the same blot or autoradiogram. Histograms show the quantification of 
32
PO4 labeling 
(% WT basal control, mean + S.E.; ** p < 0.01, WT (hDAT) AMPH vs. WT basal; # p 
< 0.05, indicated DAT forms basal vs. WT basal; * p < 0.05, WT (rDAT) AMPH vs. 
WT basal; ### p < 0.001, A558V rDAT basal vs. WT basal; n=6 (rDAT WT, A558V 
rDAT and C580A rDAT), 5 (hDAT WT, A559V), 4 (C581A hDAT)). Statistical 
analyses were done by unpaired Student’s t-test using graphpad prism software. 
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basal; p < 0.01 vs. WT basal). In contrast to WT, A559V hDAT (231 + 50% of WT 
basal; p < 0.05 vs. WT basal) and C581A hDAT (194 + 41% of WT basal; p < 0.05 vs. 
WT basal) displayed elevated basal phosphorylation levels with AMPH-mediated 
PKC-stimulation having no effect on the already elevated phosphorylation levels. This 
increased basal phosphorylation level demonstrated by ADHD associated SNP, 
A559V, suggests that it may mechanistically be contributing to ADE seen in this 
polymorphism. 
Identical experiments performed on A558V rDAT and C580A rDAT, rat homologues 
for A559V hDAT and C581A hDAT respectively displayed similar AMPH-stimulated 
increase in phosphorylation levels over basal for WT (192 + 41% of WT basal; p < 
0.05 vs. WT basal). In contrast to WT, A558V rDAT (299 + 33% of WT basal; p < 
0.001 vs. WT basal) and C580A rDAT (213 + 46% of WT basal; p < 0.05 vs. WT 
basal) displayed elevated basal phosphorylation level, which were insensitivity to 
AMPH-stimulation [9, 36, 110]. 
A558V rDAT displays increased phosphorylation at T53 
Mass-spectrometry studies have identified T53 residue on the N-terminus to be a 
proline directed phosphorylation site driven by kinases such as mitogen-activated 
protein kinase (MAPK), c-Jun N-terminal kinase (JNK) and ERK [38, 48, 51, 197]. It 
is believed that the closeness of T53 to TMD 1 causes modifications at this site 
regulate the binding and interaction of DAT with other associated proteins affecting 
the opening and closing of intracellular gates and ion flow or efflux [48, 50, 52, 53]. 
We examined the phosphorylation status of T53 using a phospho-specific T53 
antibody. LLC-PK1 cells stably expressing WT, A558V rDAT or C580A rDAT, were 
treated with vehicle or 10 μM AMPH and equal amounts of DAT were 
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immunoprecipitated for pT53 and analyzed by immunoblotting (Fig. 15) [9, 36, 38, 
110]. WT DAT displayed typical levels of T53 phosphorylation with AMPH-mediated 
stimulation causing an increase in T53 phosphorylation levels over basal (154 + 17% 
of WT basal; p < 0.01 vs. WT basal). In contrast to WT, A558V rDAT (159 + 22% of 
WT basal; p < 0.05 vs. WT basal) and C580A rDAT (168 + 17% of WT basal; p < 
0.01 vs. WT basal) displayed elevated T53 phosphorylation levels with AMPH-
mediated stimulation having no effect on the already elevated T53 phosphorylation 
levels. This result demonstrated that AMPH mediates proline directed phosphorylation 
at T53 (human equivalent being S53) affecting DA functionality and could be a factor 
causing rapid up-regulation of DAT transport capacity, which is mediated kinases such 
as MAPK, JNK and ERK. Phosphorylation at this site could also contribute to ADE 
seen by this polymorphism. 
Determining C581A hDAT to be palmitoylation deficient mutant 
C580 is the only known palmitoylation site in rDAT such that Cys to Ala substitution 
causes 1 60% reduction in palmitoylation levels and reciprocal increase in 
phosphorylation levels [36, 110]. With C581 being the human equivalent to C580, we 
hypothesized it to be a palmitoylation site. To determine if C581 is a palmitoylation 
site, we subjected LLC-PK1 cells stably expressing WT or C581A hDAT to ABE (Fig. 
16) [64, 194, 198]. In contrast to WT, C581A hDAT (49 + 8% of WT; p < 0.01 vs. 
WT) indeed displayed reduced palmitoylation levels indicating it is a palmitoylation 
site. This mutant also reciprocally demonstrated increased phosphorylation levels. The 
lack of complete loss of palmitoylation at C581A hDAT indicates the possibility of 
there being additional palmitoylation sites within hDAT. 
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Figure 15: A558V rDAT shows increased basal T53 phosphorylation levels. 
LLC-PK1 cells stably expressing the indicated rDAT forms were treated with vehicle 
or 10 μM AMPH. Equal amounts of DAT determined by immunoblotting (IB) were 
immunoprecipitated using T53 phospho-specific DAT antibody and subjected to 
immunoblotting.  
Upper panel shows representative T53 phospho-specific DAT immunoblot and 
matching total DAT immunoblot. Vertical white dividing lines indicate the 
rearrangement of lanes from the same blot. Histogram shows the quantification of T53 
phosphorylation (% WT basal control, mean + S.E.; ** p < 0.01, WT AMPH vs. WT 
basal; # p < 0.05, A558V rDAT basal vs. WT basal; ## p < 0.01, C580A rDAT basal 
vs. WT basal; n=7). Statistical analyses were done by unpaired Student’s t-test using 
graphpad prism software. 
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Figure 16: C581A hDAT is a palmitoylation deficient mutant. 
LLC-PK1 cells stably expressing WT or C581A hDAT were assessed for 
palmitoylation by ABE. Upon blocking the free Cys thiol residues with 20 mM 
MMTS, cell lysates were treated with 0.7 M NH2OH or 50 mM Tris-HCl (control) 
followed by reaction with 0.4 mM sulfhydryl-specific biotinylating reagent. Equal 
amounts of DAT determined by immunoblotting (IB) were subjected to neutrAvidin 
extraction followed by immunoblotting.  
Upper panel shows representative ABE blot and matching total DAT immunoblot. 
Vertical white dividing lines indicate the rearrangement of lanes from the same blot. 
Histogram shows the quantification of DAT palmitoylation (% WT, mean + S.E.; ** p 
< 0.01, C581A vs. WT; n=4). Statistical analysis was done by unpaired Student’s t-test 
using graphpad prism software. 
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ADHD associated SNP, A559V hDAT and its rat homologue, A558V rDAT, display 
decreased palmitoylation 
We have shown that A559V hDAT and A558V rDAT have elevated basal 
phosphorylation levels consistent with ADE and that this increase in phosphorylation 
is insensitive to AMPH-stimulation. With DAT being reciprocally regulated by 
palmitoylation and phosphorylation, we next examined WT, A559V hDAT or A558V 
rDAT for their palmitoylation status by ABE (Fig. 17) [110]. In contrast to WT, 
A559V hDAT (69 + 5% of WT; p < 0.01 vs. WT) and A558V rDAT (61 + 4% of WT; 
p < 0.01 vs. WT) displayed decreased palmitoylation levels, demonstrating these 
DATs are palmitoylation deficient mutants. With the rationale for decreased 
palmitoylation not well understood, we believe that the Ala to Val substitution close to 
the palmitoylation site is a factor causing reduction in palmitoylation. The presence of 
bulkier Val may mechanistically be hindering palmitoylation at C581 [64, 194, 198]. 
Phosphorylation deficient hDAT and rDAT mutants show enhanced palmitoylation 
status 
Among the many Ser/Thr residues on the DAT N-terminus, S7 and T53 residues on 
rDAT have been validated as phosphorylation sites (human equivalent being S7 and 
S53 respectively) [38, 49]. Activated by various kinases, N-terminal phosphorylation 
plays an important role in mediating DA efflux, regulating DAT binding to its partner 
proteins and down-regulation of DAT functional capacity [9, 39-41, 48, 49, 51, 91]. 
As DAT is reciprocally regulated [110], we examined T53A rDAT, S7A and S53A for 
their palmitoylation status (Fig. 18) [64, 194, 198].  
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Figure 17: A559V hDAT and A558V rDAT display decreased palmitoylation levels. 
LLC-PK1 cells stably expressing the indicated hDAT or rDAT forms were assessed for 
palmitoylation by ABE. Upon blocking the free Cys thiol residues with 20 mM 
MMTS, cell lysates were treated with 0.7 M NH2OH or 50 mM Tris-HCl (control) 
followed by reaction with 0.4 mM sulfhydryl-specific biotinylating reagent. Equal 
amounts of DAT determined by immunoblotting (IB) were subjected to neutrAvidin 
extraction followed by immunoblotting.  
Upper panels show representative ABE blots and matching total DAT immunoblots. 
Vertical white dividing lines indicate the rearrangement of lanes from the same blot.  
Histograms show the quantification of DAT palmitoylation (% WT, mean + S.E.; ** p 
< 0.01, indicated DAT forms vs. WT; n=3). Statistical analyses were done by unpaired 
Student’s t-test using graphpad prism software. 
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Figure 18: Phosphorylation deficient hDAT and rDAT mutants show enhanced 
palmitoylation levels. 
LLC-PK1 cells stably expressing the indicated hDAT or rDAT forms were assessed for 
palmitoylation by ABE. Upon blocking the free Cys thiol residues with 20 mM 
MMTS, cell lysates were treated with 0.7 M NH2OH or 50 mM Tris-HCl (control) 
followed by reaction with 0.4 mM sulfhydryl-specific biotinylating reagent. Equal 
amounts of DAT determined by immunoblotting (IB) were subjected to neutrAvidin 
extraction followed by immunoblotting. 
Upper panels show representative ABE blots and matching total DAT immunoblots. 
Vertical white dividing lines indicate the rearrangement of lanes from the same blot. 
Histograms show the quantification of DAT palmitoylation (% WT, mean + S.E.; ** p 
< 0.01, indicated DAT forms vs. WT; * p < 0.05, S53A hDAT vs. WT; n=8 (hDAT 
WT), 4 (rDAT WT, T53A rDAT, S7A hDAT, S53A hDAT)). Statistical analyses were 
done by unpaired Student’s t-test using graphpad prism software. 
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LLC-PK1 cells stably expressing WT, T53A rDAT, S7A hDAT or S53A hDAT were 
subjected to ABE. In contrast to WT, T53A rDAT (133 + 8% of WT; p < 0.01 vs. 
WT), S7A hDAT (196 + 35% of WT; p < 0.01 vs. WT) and S53A hDAT (155 + 32% 
of WT; p < 0.05 vs. WT) displayed increased palmitoylation levels. These results 
strengthen the concept of reciprocal regulation of post-translational modifications, 
though the actual mechanism for such a reciprocal phenomenon in these mutants is 
still not well understood. 
61 
 
DISCUSSION 
DAT is an important neurotransmission regulator which controls the duration of DA 
neurotransmission by clearing the synapse of DA [3]. Abnormal levels of DA in the 
mesescephalon is associated with neurological disorders such as PD, AD, ADHD, 
ASD, BPD, drug abuse and addiction with some of these disorders also being 
associated with SNPs in DAT [6, 8-10, 16-21, 26, 41, 112, 199-201]. DAT undergoes 
various post-translational modifications, including phosphorylation and palmitoylation 
which plays a role in regulating DAT function affecting DAT down-regulation, 
membrane raft partitioning, membrane trafficking and mobility, DAT surface 
expression and Vmax [8, 9, 26, 36, 48, 56, 62, 113, 114, 164, 169]. These post-
translational modifications reciprocally regulate each other such that increased 
phosphorylation leads to decreased palmitoylation and visa versa [49, 56, 110, 111]. 
Drugs such as AMPH mediate PKC-stimulated increase in N-terminal DAT 
phosphorylation, a condition stimulating ADE [40, 136]. An ADHD associated rare 
hDAT SNP, A559V displays total and surface DAT levels and DA uptake levels 
similar to WT but shows DA efflux independent of AMPH stimulation suggesting that 
differences exist between WT and A559V hDAT towards their ability to interact with 
AMPH [9, 40, 162, 164, 169, 193, 202]. Studies with ASD showed A559V has a 
reduced ability to transport AMPH stating a conformational alteration might be 
hampering its dynamics to transport AMPH [169].  
We here demonstrate A559V hDAT and its rat homologue, have elevated 
phosphorylation levels, including specific modification at T53, a proline directed  
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phosphorylation site specific for rDAT, supporting a role for phosphorylation at this 
site in DA efflux. In addition, elevated phosphorylation levels in this mutant were 
independent of AMPH-stimulation and AMPH failed to have an effect on the already 
elevated phosphorylation levels consistent with reduced ability of this mutant to 
transport AMPH. We also showed similar increased phosphorylation levels for C581A 
hDAT and C580A rDAT which are palmitoylation deficient mutants. Thus, we believe 
increased phosphorylation levels mechanistically contribute to ADE seen for this 
polymorphism. With T53 showing increased phosphorylation, we believe this proline 
directed phosphorylation site could be a factor causing a rapid increase in DAT 
transport capacity, which is mediated by MAPK, JNK and ERK. Similar 
phosphorylation occurring at S53 in hDAT could drive DA efflux. 
With recent findings showing DAT is reciprocally regulated with regard to 
phosphorylation and palmitoylation, we analyzed the palmitoylation status for A559V 
hDAT and A558V rDAT to find that these mutants displayed decreased palmitoylation 
levels. We also demonstrate C581A hDAT, to be a palmitoylation deficient mutant, 
which showed reciprocal increased phosphorylation levels. With A559V hDAT and 
A558V rDAT displaying reciprocally regulated post-translational modifications, we 
believe that the close proximity of the mutated residue A559V to the known 
palmitoylation site, C581, could be the driving force.  
A559 is located at the top extracellular side of TMD 12. It shares close proximity to 
C581, a palmitoylation site that is present on the intracellular side of TMD 12. The 
mutation of Ala to Val at 559 residue, makes this site bulkier that may cause structural 
change within TMD 12. This hindrance could make C581 move away from the DAT 
core region making it lose its flexibility. This could affect C581 from undergoing 
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palmitoylation and the C-terminus to cap the cytoplasmic gate. Thus this altered 
palmitoylation status of A559V hDAT and A558V rDAT could affect its 
phosphorylation status by an unknown mechanism which could stimulate ADE.  
Another concept driving this reciprocal regulation of these post-translational 
modifications in A559V hDAT could be the N-terminal phosphorylation which is 
supported by PKC-stimulation.  DAT is a 12 TMD helical structure with TMDs 1, 3, 6 
and 8 forming the central core binding pocket with the substrate translocation 
occurring in DAT via a alternating access mechanism [3, 203]. With DAT 
phosphorylation and palmitoylation both occurring outside the core of the protein, we 
speculate that the amino acid residues involved in these post-translational 
modifications could be interacting with binding partners, gating residues in a process 
of impacting the overall functioning, structure and orientation, duration of transport 
cycle of DAT which in turn affect other post-translational modifications [10, 36, 41, 
53, 88, 110, 204].  
We also demonstrated increased palmitoylation status for phosphorylation deficient 
mutants including T53A rDAT, S7A hDAT and S53A hDAT. Although the actual 
mechanism for this phenomenon is not known we believe these mutants would be 
harboring similarly targeted phenomenon to bring about this reciprocal post-
translational modifications. Together these results strongly support reciprocal 
regulation for phosphorylation and palmitoylation in DAT. 
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CHAPTER III 
ALTERED MEMBRANE LOCALIZATION AND MOBILITY IN ADHD 
ASSOCIATED DOPAMINE TRANSPORTER MUTANT A559V LINKED TO 
ALTERED PHOSPHORYLATION/PALMITOYLATION STATUS 
ABSTRACT 
In the central nervous system, the presynaptic dopamine transporter (DAT, SLC6A3) 
regulates synaptic dopamine (DA) signaling by clearing the DA from the synapse into 
the presynaptic neuron. Dysregulated DA clearance and/or DAT associated 
polymorphisms have been linked to several neurological diseases including  bipolar 
disorder (BPD), Parkinson’s disease (PD), attention-deficit hyperactivity disorder 
(ADHD) and autism although the role of DAT dysfunction in these diseases is not 
clearly understood. ADHD associated human DAT (hDAT) single nucleotide 
polymorphism (SNP) A559V hDAT displays ADE and elevated N-terminal 
phosphorylation independent of amphetamine (AMPH) stimulation. With membrane 
rafts being the preferred site for localization of phosphorylated DAT, we here 
demonstrate increased DAT localization in membrane raft microdomains over non-raft 
microdomains for A559V hDAT and its rat homologue, A558V rat DAT (rDAT) and 
mutants having elevated phosphorylation levels. This enrichment of phosphorylated 
DAT in membrane raft microdomain is driven by AMPH-stimulation in the wildtype 
(WT). 
With palmitoylation known to influence membrane trafficking and mobility, we 
confirm palmitoylation to be a factor regulating lateral membrane mobility, such that 
stimulation of phosphorylation drives an increase in lateral membrane mobility via a 
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reciprocal decrease in palmitoylation. We also demonstrate A559V hDAT, A558V and 
other palmitoylation deficient mutants have increased lateral membrane mobility with 
reciprocal results for phosphorylation deficient mutants T53A rDAT, S7A hDAT, 
S53A hDAT (human homologue for T53A rDAT).  
With enhanced localization of phosphorylated DAT in membrane raft microdomain, 
we believe membrane rafts serve as a platform for ADE displayed by A559V hDAT. 
For ADHD associated A559V, we believe that its closeness to the palmitoylation site, 
C581, is a factor causing its decrease in palmitoylation status, which in-turn drives the 
increase in lateral membrane mobility. This decrease in palmitoylation is also the 
driving force for increased phosphorylation levels and localization of DAT in 
membrane raft region. 
Although we lack a complete understanding of how palmitoylation affects lateral 
membrane mobility and membrane microdomain distribution, together, our data 
provides valuable information regarding palmitoylation being a factor contributing 
towards regulating DAT localization in membrane raft and its lateral membrane 
mobility for ADHD associated A559V and other phosphorylation and palmitoylation 
deficient DAT mutants.  
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INTRODUCTION 
The neurotransmitter dopamine (DA) plays a critical role in controlling motor 
activities, reward, pleasure and locomotive abilities [6, 9, 14]. The rapid synaptic 
clearance of DA is controlled by the dopamine transporter (DAT), a 12 
transmembrane spanning domain (TMD) plasma membrane protein belonging to the 
solute carrier 6 (SLC6) gene family of NA
+
/Cl
-
 coupled transporters [2-4, 6, 9, 31, 35, 
205, 206]. Functionally, this clearance of DA via DAT controls the intensity and 
duration of the dopaminergic signaling maintaining DA homeostasis. 
DAT is the primary target for abused psychoactive drugs such as amphetamine 
(AMPH) and cocaine (COC), which act as substrate and uptake blocker respectively 
[2, 3, 205, 206]. While DAT bound COC prevents the binding and movement of DA 
into the pre-synaptic neuron, affecting DAT regulatory properties, AMPH is 
transported via DAT into the pre-synaptic neuron, where it disrupts the potential 
gradient of the synaptic vesicles eventually causing DA efflux (reverse transport) 
without affecting DA transport capacity, DA uptake and the surface expression of 
DAT [3, 40, 48, 115-117, 119, 196]. DAT is associated with many neurological and 
psychological diseases, in which DAT either has dysfunction and/or polymorphism. 
Such disorders are schizophrenia, bipolar disorder (BPD), Parkinson’s disease (PD), 
autism spectrum disorder (ASD), obsessive compulsive disorder (OCD), attention-
deficit hyperactivity disorder (ADHD) and addiction although the actual role of DAT 
dysfunctions and/or polymorphisms in these disorders is not well understood [6, 9, 17, 
18, 20, 191, 207]. 
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DAT undergoes tightly regulated post-translational modifications. The two 
modifications that are of our interest are phosphorylation and palmitoylation. These 
modifications are reciprocally regulated and between them modulate functions such as 
protein-protein interaction, membrane trafficking, DAT signaling and lateral 
membrane mobility [9, 36, 56, 60, 95, 102, 127, 137, 208, 209]. DAT is 
phosphorylated by kinases such as protein kinase C (PKC) or calcium/calmodulin-
dependent protein kinase II (CaMKII) which cause DAT interaction with binding 
partners, anomalous DA efflux (ADE), DAT down-regulation, endocytosis and 
reduction in DA transport capacity [46, 57, 58, 210, 211]. AMPH is able to trigger 
PKC-stimulated N-terminal DAT phosphorylation and trigger DA efflux [40, 57, 202, 
212].  
DAT undergoes S-palmitoylation, the reversible addition of a saturated fatty acid 
moiety (palmitate) via a thioester bond to Cys. Palmitoylation is brought about by 
specific enzymes called palmitoyl acyltransferases (PATs) while removal of the 
palmitate group is catalyzed by palmitoyl-protein thioesterases (PPTs) [69]. 
Palmitoylation affects DAT transport kinetics, degradation and protein kinase 
stimulated down regulation [36, 72]. The driving force behind palmitoylation is 
thought to be the properties of the palmitate group, its hydrophobicity/membrane 
affinity and its preference for the cholesterol rich membrane rafts [71].  
DAT present on the plasma membrane is distributed between cholesterol-rich 
membrane raft microdomains and cholesterol poor membrane non-raft microdomain 
with membrane rafts playing a role in compartmentalization of cellular processes 
associated with DAT internalization, lateral membrane mobility and endocytotic cargo 
delivery regulating DAT function [56, 90, 137, 172, 175, 213, 214]. PKC-stimulated 
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phosphorylated DAT is localized in membrane raft microdomains over non-raft 
microdomains suggesting that membrane rafts are preferred sites for DAT 
phosphorylation localization [56, 136, 140]. With AMPH-mediated PKC-stimulation 
causing DA efflux, membrane rafts may serve as a platform for this efflux. 
A recently discovered ADHD, BPD and ASD associated single nucleotide 
polymorphism (SNP) in human DAT (hDAT) is A559V [9, 162, 164, 169]. This SNP 
displayed ADE independent of AMPH-stimulation and altered DAT transport function 
[9, 18, 193]. Findings have shown that A559V hDAT has increased basal 
phosphorylation, a condition promoting ADE [8, 9, 169] [Chapter II].   
With membrane rafts being the preferred site for phosphorylated DAT localization, we 
studied the membrane microdomain distribution for ADHD associated SNP, A559V 
hDAT and its rat homologue, A558V rat DAT (rDAT) along with palmitoylation 
deficient mutants (C581A hDAT and C580A rDAT) which showed reciprocal elevated 
phosphorylation. We also studied the effect of AMPH on the membrane raft and non-
raft microdomain localization for these mutants. 
Being a plasma membrane protein, membrane trafficking of DAT is an important 
component of its regulatory function, with dysregulation of membrane trafficking 
known to be a risk determinant for many disorders [167, 172]. With previous studies 
having shown A559V hDAT and A558V rDAT to be palmitoylation deficient mutants, 
we studied the lateral membrane mobility for A559V hDAT, A558V rDAT and other 
palmitoylation and phosphorylation deficient mutants. We also studied the effect of 
AMPH and phorbol 12-myistate, 13-acetate (PMA) on mobility, further analyzing if 
palmitoylation is a factor driving lateral membrane mobility. 
69 
 
EXPERIMENTAL METHODS 
Cell culture and site directed mutagenesis 
Plasmids containing the coding sequence for mutant DATs were generated by codon 
substitution in a pcDNA 3.0 vector containing WT hDAT or rDAT using the 
Stratagene QuikChange® Kit and were verified by sequencing (Eurofins MWG). 
Lewis lung carcinoma-porcine kidney (LLC-PK1) cells were transfected with 
individual plasmids and selected for stable DAT expression with 800 µg/ml geneticin 
(G418 sulfate). Plasmids containing coding sequence for EYFP-tagged WT DATs 
were generated by insertion of the WT hDAT or rDAT coding sequence between the 
Kpn I and ECoR I endonuclease cleavage sites in an EYFP-C1 (Clontech) vector. 
Plasmids containing the coding sequence for EYFP-tagged DAT mutants were 
generated by codon substitution in the EYFP-C1 vector containing WT hDAT or 
rDAT sequence using the Stratagene QuikChange® Kit and were verified by 
sequencing (Eurofins MWG). Neuronal (N2A) cells were transiently transfected with 
the EYFP-DAT vectors to express yellow fluorescent protein (YFP)-tagged DATs. 
LLC-PK1/N2Acells were grown in 12-well culture plates and were transfected with 
1.4 μg plasmid/well and XtremeGene transfection reagent (Roche). Stable 
transformants were selected 24-48 hours post transfection while transient 
transformants were used for experiments 24-48 hours post transfection. For stable 
transfections, the cells were maintained under selection by adding 800 μg/mL G418 
sulfate to the culture medium. Transfected LLC-PK1 cells were maintained in α-
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minimum essential medium (AMEM) supplemented with 2 mM L-glutamine, 5% fetal 
bovine serum (FBS), 200 μg/mL G418 sulfate and 1X penicillin/streptomycin while 
transfected N2A cells were maintained in dulbecco’s modified eagle’s medium 
(DMEM) supplemented with 10% FBS and 1X penicillin/streptomycin. Cells were 
incubated in an incubation chamber gassed with 5% CO2 at 37°C. DAT expression 
levels in transfected cells was verified by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and immunoblotting of the cellular lysates against DAT 
specific antibodies. The YFP-DAT expressing cells were additionally checked for the 
fluorescence levels by confocal microscopy. 
Confocal microscopy and fluorescence recovery after photobleaching (FRAP) 
N2A cells transiently expressing YFP-tagged WT or mutant DAT were plated on 1 
mm glass coverslips and allowed to grow to ~50% confluence before confocal 
imaging and FRAP analysis was performed using a Zeiss 510 META laser scanning 
confocal microscope.  
For palmitoylation inhibition studies, cells were treated with vehicle or 15 μM 2-
bromopalmitate (2BP) for 3 hours at 37°C prior to confocal imaging and FRAP 
analysis. For phosphorylation stimulation studies, cells were treated with vehicle or 10 
μM AMPH or 1 μM PMA for 20 minutes or 30 minutes respectively at 37°C prior to 
confocal imaging and FRAP analysis. 
During each FRAP run, cells were excited at 488/514 nm with an argon laser (2% 
power) through a 100X oil immersion objective followed by separation of the excited  
wavelength from the emitted wavelength using a 530 nm long pass filter. Following 
the excitation, a series of images were captured at ~4 seconds intervals to establish a 
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fluorescence intensity baseline for a 30 μm diameter circular region of interest (ROI) 
on the cellular plasma membrane. The ROIs were then photobleached at 514 nm with 
an argon laser (100% power), keeping the pinhole fully open to ensure complete 
bleaching through the ROI. Following photobleaching, a total of 100 images were 
captured for analysis of the time taken for fluorescence recovery (T ½) after 
photobleaching. This analysis was done using ImageJ software and the exponential 
recovery function (F(x) =F"∞"+A(exp(-xτ))). Experiments were independently 
performed three or more times with three or more independent cells being examined in 
each experiment. Results are reported as mean ± standard error. Statistical analyses 
were done by unpaired Student’s t-test using graphpad prism software. 
Sucrose density gradient centrifugation 
Membrane raft fractions were isolated by a modified discontinuous sucrose density 
gradient centrifugation technique [90]. LLC-PK1 cells stably expressing WT or mutant 
DATs were grown in 150 mm culture plates until ~80% confluent. After a quick wash 
with ice-cold Kreb’s-Ringer HEPES (KRH) buffer (25 mM HEPES, 125 mM sodium 
chloride, 1.3 mM calcium chloride, 4.8 mM potassium chloride, 1.2 mM potassium 
dihydrogen phosphate, 1.2 mM magnesium sulfate, 5.6 mM glucose, pH 7.4) cells 
were treated with vehicle or 10 μM AMPH for 20 minutes at 37°C. Following washes 
the cells were solubilized with 750 μL 1% BRIJ-58 in TNEB (10 mM tris-HCl, 150 
mM sodium chloride, 1 mM EDTA, pH 7.5) for 1 hour at 4°C with end-over-end 
mixing. After centrifugation of the lysate at 1,000 X g for 10 minutes at room 
temperature, 750 μL of the supernatant fraction was brought to 40% sucrose 
concentration by adding equal volume of 80% sucrose in TNEB. This 40% sucrose-
supernatant mix was underlayed into the bottom of an SW41 centrifuge tube 
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containing a discontinuous sucrose gradient composed of 5.5 mL of 30% sucrose 
under 5 mL of 5% sucrose in TNEB. The tubes were centrifuged at 36,000 rpm for 18 
hours at 4°C followed by collection of 500 μL fractions from each tube, starting from 
the top of the tube. 25 μL of each fraction was mixed with 7 μL 5X laemmli sample 
buffer and subjected to SDS-PAGE and immunoblotting for DAT. The polyvinylidene 
difluoride (PVDF) membranes were stripped of antibodies and reprobed for transferrin 
receptor and flotillin-1. Fractions were also assayed for total protein and cholesterol 
using BCA protein assay and a cholesterol E assay kit (Wako) respectively. The total 
protein and cholesterol levels were quantified using a molecular devices microplate 
reader at the appropriate wavelength. Fractions 1-8 did not contain detectable levels of 
DAT or other protein markers (data not shown). Experiments were independently 
performed three or more times. Results are reported as mean ± standard error. 
Statistical analyses were done by One-Way ANOVA with Tukey's post-hoc test using 
graphpad prism software. 
Immunoblotting 
SDS-PAGE was performed using 4-20% tris/glycine-polyacrylamide gels. Proteins 
were resolved by electrophoresis (150 Volts for 1.45 hours) in 1X tris-glycine running 
buffer. The proteins were transferred to 0.2 μm PVDF membranes (35 Volts for 1.45 
hours) in 1X transfer buffer (25 mM tris, 192 mM glycine, 0.1% SDS, 20% methanol) 
at 4°C. Membranes were blocked overnight by incubation with 3% bovine serum 
albumin (BSA)/phosphate buffer saline (PBS; 1.37 M sodium chloride, 2.7 mM 
potassium chloride, 100 mM disodium phosphate, 18 mM potassium dihydrogen 
phosphate, pH 7.4) at 4°C. Blocked membranes were probed for 1 hour at RT with 
DAT specific goat polyclonal antibody raised against amino acids 601 to 620 of the C-
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terminus of hDAT or DAT specific mouse monoclonal antibody raised against 
synthetic peptide 16 containing amino acids 42 to 59 of the N-terminus of rDAT 
(1:1000 dilution in 3% BSA/PBS). The bound antibodies were detected by incubating 
the PVDF membranes for 1 hour at RT with anti-goat or anti-mouse immunoglobulin 
(IgG) 2° antibody linked to alkaline phosphatase (1:5000 dilution in 3% BSA/PBS), 
with 5 washes of 0.1% tween-20/PBS after each antibody treatment followed by 
incubation of the membranes with 3 ml alkaline phosphatase substrate for 5 minutes. 
The membranes were sandwiched between plastic film and imaged on a BioRad Image 
Doc System and quantified using Quantity-1.0® analysis software.  
Equipment 
Transfected LLC-PK1 and N2A cells were maintained in a Nuair 2700-30 water 
jacketed CO2 incubator and handled in a Nuair class II type A/B3 biological safety 
cabinet laminar flow hood. Mutagenesis via PCR was performed using a thermocycler 
from Eppendorf.  
Cellular lysates were centrifuged using a Beckman Coulter
TM
 Microfuge® 16 or 
Microfuge® 22R microcentrifuge. Sucrose density gradients were centrifuged using 
an SW41 swing bucket rotor in a Beckman Coulter
TM
 LE-80 ultracentrifuge.  
Total protein and cholesterol levels were assayed using Molecular Devices microplate 
reader. 
Confocal imaging and FRAP studies for YFP-tagged DATs was perform using a Zeiss 
(Germany) 510 META laser scanning confocal microscope and the image analysis 
was done using Image J software (NIH).  
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SDS-PAGE and protein transfer to PVDF membranes was performed using an XCell 
SureLock
TM 
electrophoresis apparatus and an XCell II
TM
 Blot module electrophoresis 
transfer cell respectively from Invitrogen. The power supply used to control both the 
electrophoresis apparatus and electrophoresis transfer cell was also from Invitrogen. 
Illuminescence from PVDF membranes were imaged using a Bio-Rad gel 
documentation system and analyzed using Bio-Rad Quantity-1.0® software. All 
statistical analyses were done using graphpad prism software.  
Materials 
DMEM, AMEM, G418 sulfate, 1X Penicillin/Streptomycin, and L-Glutamine were 
from Corning Cellgro (Manassas, VA, USA); FBS was from Atlanta Biologicals 
(Atlanta, GA, USA); XtremeGene Transfection Reagent was from Roche 
(Indianapolis, IN, USA); Magnesium Sulfate, Glucose, AMPH, 2-BP, Colorburst 
Molecular Mass Standard Markers, Brij-58 and anti-mouse IgG 2° antibody linked to 
alkaline phosphatase were from Sigma Aldrich (St. Louis, MO, USA); Dimethyl 
Sulfoxide (DMSO), Sucrose, HEPES, EDTA, Protease Inhibitor Tablets, Tween-20, 
Triton X-100, Sodium Chloride, BSA, Sodium Phosphate, Potassium Chloride, 
Disodium Phosphate, Calcium Chloride, Potassium Dihydrogen Phosphate, SDS, 
Methanol, Tris-HCl, Glycine and PVDF membranes were from Fisher Scientific 
(Waltham, MA, USA); 4-20% tris/glycine-polyacrylamide gels were from Lonza 
(Walkerville, MD, USA); DAT specific mouse monoclonal antibody raised against 
synthetic peptide 16 containing amino acids 42 to 59 of the N-terminus of rDAT was 
from Cell Essentials (Boston, MA, USA); Alkaline phosphatase substrate (ImmunStar) 
was from Bio-Rad (Hercules, CA, USA); DAT specific goat polyclonal antibody 
raised against amino acids 601 to 620 of the C-terminus of hDAT and anti-goat IgG 2° 
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antibody linked to alkaline phosphatase were from Santa Cruz Biotechnology (Dallas, 
TX, US); PMA was from Calbiochem (San Diego, CA, USA); transferrin receptor and 
flotillin-1 were from BD Sciences (San Jose, CA, USA); cholesterol E assay kit was 
from Wako Diagnostics (Richmond, VA, USA). 
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RESULTS 
ADHD associated SNP, A559V hDAT and its rat homologue, A558V rDAT, display 
increased membrane raft microdomain association 
DAT undergoes N-terminal phosphorylation which is stimulated by protein kinases 
and proline directed kinases such as PKC and extracellular signal regulated pathway 
(ERK) respectively [40, 41, 49, 93, 95]. This phosphorylation is elevated upon 
treatment of PKC activators such as PMA and/or psychostimulant drugs such as 
AMPH such that this elevated phosphorylation mediates DA efflux and is 
accompanied by DAT endocytosis [40, 49, 129, 136, 140, 195, 196]. 
DAT is partitioned between membrane raft and non-raft microdomains that appear to 
affect multiple biochemical and regulatory properties of DAT. The membrane 
microdomain distribution of DAT suggests membrane rafts to be sites of relative lower 
constitutive phosphorylation and/or higher dephosphorylation which could be related 
to compartmentalization [56]. Previous studies have shown PMA-stimulation to cause 
an increase in localization of phosphorylated DAT in membrane raft microdomains 
suggesting it to be the preferred site for localization of phosphorylated DAT [40, 56].  
An ADHD associated SNP, A559V hDAT, shows ADE which was supported by 
elevated levels of basal phosphorylation [8, 9, 136]. With phosphorylated DAT 
localized in membrane raft microdomains, we examined the membrane microdomain 
distribution for A559V, and its rat homologue, A558V rDAT along with other 
palmitoylation deficient mutants, C581A hDAT and C580A rDAT, which showed  
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elevated phosphorylation levels [36, 56, 110] [Chapter II]. LLC-PK1 cells stably 
expressing WT, A559V hDAT, C581A hDAT or their respective rat homologues were 
subjected to 1% Brij-58 lysis followed by sucrose density gradient centrifugation and 
immunoblotting (Fig. 19). In contrast to WT which showed typical levels of 
membrane raft and non-raft distribution, A559V hDAT, A558V rDAT and mutants 
with elevated phosphorylation levels displayed increased membrane raft microdomain 
localization over non-raft microdomain distribution (Raft: hDAT WT, 51 + 1; A559V 
hDAT, 62 + 2; C581A hDAT, 69 + 1; rDAT WT, 41 + 3; A558V rDAT, 55 + 2; 
C580A rDAT, 57 + 1). With AMPH mediating PKC-stimulated phosphorylation that 
is associated with ADE, we examined the effect of AMPH on WT, A559V hDAT, 
C581A hDAT and their respective rat homologues. LLC-PK1 cells stably expressing 
WT, A559V hDAT, C581A hDAT or their respective rDAT homologues were treated 
with vehicle or 10 μM AMPH, followed by 1% Brij-58 lysis, sucrose density gradient 
centrifugation and immunoblotting (Fig. 20). In contrast to WT which showed typical 
levels of membrane raft and non-raft distribution, AMPH-stimulation resulted in 
increased DAT membrane raft microdomain localization over non-raft microdomain 
distribution (Raft: hDAT WT (basal), 47 + 2; hDAT WT (AMPH), 64 + 1; rDAT WT 
(basal), 33 + 3; rDAT WT (AMPH), 59 + 3). A559V hDAT, A558V rDAT and 
mutants with elevated phosphorylation levels failed to show any additional shift in 
membrane raft microdomain distribution from its earlier elevated DAT membrane raft 
localization. 
These results indicate that mutants displaying ADE and/or elevated phosphorylation, 
show increased membrane raft localization, suggesting membrane raft microdomains 
serve as platforms for ADE.  
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Figure 19: A559V hDAT and A558V rDAT display increased membrane raft 
microdomain localization. 
LLC-PK1 cells stably expressing the indicated hDAT or rDAT forms were subjected to 
1% Brij-58 lysis followed by sucrose density gradient centrifugation. Aliquots of 
gradient fractions 9-24 were immunoblotted using the indicated antibodies. 
Representative blots for DAT, transferrin receptor and flotillin distribution between 
membrane raft and non-raft populations are shown. Designation of raft - non-raft are 
indicated above the blots. The gradient fractions were also analyzed for total protein 
and cholesterol contents with mean ± S.E. for each fraction shown in the scatterplots 
on the right. 
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Fig 19: continued. 
Histograms show the quantification of DAT in raft (black bar) and non-raft (gray bars) 
fractions (% Total, mean + S.E.; ** p < 0.01, A559V hDAT (raft) vs. WT (raft); *** p 
< 0.01, C581A hDAT (raft) vs. WT (raft); * p < 0.05, indicated DAT forms (raft) vs. 
WT (raft); ## p < 0.01, A559V hDAT (non-raft) vs. WT (non-raft); ### p < 0.01, 
C581A hDAT (non-raft) vs. WT (non-raft); # p < 0.05, indicated DAT forms (non-
raft) vs. WT (non-raft); n=8 (hDAT WT), 6 (rDAT WT, A559V hDAT, A558V 
rDAT), 3 (C581A hDAT, C580A rDAT)). Statistical analyses were done by One-Way 
ANOVA with Tukey's post-hoc test using graphpad prism software. 
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Figure 20: AMPH induces an increase in WT DAT membrane raft microdomain 
localization. 
LLC-PK1 cells stably expressing the indicated hDAT or rDAT forms were treated with 
vehicle or 10 μM AMPH followed by 1% Brij-58 lysis. The lysates were subjected to 
sucrose density gradient centrifugation and aliquots of gradient fractions 9-24 were 
immunoblotted for DAT. Representative blots for DAT distribution between 
membrane raft and non-raft populations are shown. Designation of raft - non-raft are 
indicated above the blots.  
 
81 
 
Fig 20: continued. 
Histograms show the quantification of DAT in raft [black bar] and non-raft [gray bars] 
fractions (% Total, mean + S.E.; ** p < 0.01, hDAT WT, rDAT WT (raft) (AMPH) 
vs.WT hDAT WT, rDAT WT (raft) (basal); ## p < 0.01, hDAT WT, rDAT WT (non-
raft) (AMPH) vs. WT hDAT WT, rDAT WT (non-raft) (basal); n=3). Statistical 
analyses were done by One-Way ANOVA with Tukey's post-hoc test using graphpad 
prism software. 
  
82 
 
ADHD associated SNP, A559V hDAT and its rDAT homologue, A558V rDAT, 
display increased lateral membrane mobility 
Membrane trafficking is an important DAT regulatory factor and it plays a role in 
maintaining DAT functional homeostasis. Previous studies have shown A559V hDAT 
and A558V rDAT to be palmitoylation deficient mutants [Chapter II]. Since 
palmitoylation influences membrane trafficking, mobility and microdomain 
distribution, we examined the lateral membrane mobility for A559V hDAT, A558V 
rDAT and other palmitoylation deficient mutants.  
N2A cells transiently expressing YFP-tagged WT, A559V hDAT, C581A hDAT or 
their rat homologues were subjected to FRAP analysis (Fig. 21). In contrast to WT, 
A559V hDAT, C581A hDAT and their rat homologues displayed increased lateral 
membrane mobility (lower T ½ values) (T ½: hDAT WT, 45 + 4; A559V hDAT, 24 + 
2; C581A hDAT, 20 + 41; rDAT WT, 40 + 4; A558V rDAT, 21 + 2; C580A rDAT, 20 
+ 2). Our experiments [Chapter II] as well as previous studies [8, 9, 169] have shown 
that A559V hDAT displays elevated levels of phosphorylation which is associated 
with phosphorylation stimulated ADE. With AMPH stimulating PKC-mediated 
phosphorylation, we also examined the effect of AMPH on the lateral membrane 
mobility of WT, A559V hDAT and their rat homologues. The lateral membrane 
mobility was also studied in presence of PMA, a positive control for phosphorylation 
stimulation. 
N2A cells transiently expressing YFP-tagged WT, A559V hDAT or their rat 
homologues were treated with vehicle or 10 μM AMPH or 1 μM PMA, followed by 
FRAP analysis (Fig. 22). AMPH and PMA treatments resulted in an increase in lateral 
membrane mobility (lower T ½ values) for WT. A559V hDAT and A558V rDAT  
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Figure 21: A559V hDAT and C581A and their rDAT homologues display increased 
lateral membrane mobility. 
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Fig 21: continued. 
N2A cells transiently expressing the indicated YFP-tagged hDAT or rDAT forms were 
subjected to FRAP analysis. The confocal images depict representative YFP-tagged 
DAT cell fluorescence at pre-bleach, bleached and after recovery time points during 
FRAP analysis with the circle showing the ROI used for photobleaching. The recovery 
curves display the fluorescence recovery for each DAT line after photobleaching. The 
histograms show the quantification of the time taken (sec) by each DAT to recover 
post photobleaching (Time of Recovery (sec), mean + S.E.; *** p < 0.001, A559V 
hDAT vs. WT; ** p < 0.01, indicated DAT forms vs. WT; n=30 (hDAT WT), 36 
(rDAT WT), 23 (A559V hDAT), 22 (A558V rDAT), 12 (C581A hDAT), 22 (C580A 
rDAT); n=number of cells analyzed). Statistical analyses were done by unpaired 
Student’s t-test using graphpad prism.  
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Figure 22: A559V hDAT and A558V rDAT display increased lateral membrane 
mobility equivalent to that induced by AMPH treatment. 
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Fig 22: continued. 
N2A cells transiently expressing the indicated YFP-tagged hDAT or rDAT forms were 
treated with vehicle or 10 μM AMPH or 1 μM PMA followed by FRAP analysis. The 
recovery curves display the fluorescence recovery for each DAT line after 
photobleaching. The histograms show the quantification of the time taken [sec] by 
each DAT to recover post photobleaching (Time of Recovery (sec), mean + S.E.; * p < 
0.05, indicated DAT forms (AMPH), (PMA) vs. WT (basal); ** p < 0.01, indicated 
DAT forms (basal), (AMPH), (PMA) vs. WT (basal); *** p < 0.001, A558V rDAT 
(basal) vs. WT (basal); n=21 (hDAT WT basal, rDAT WT basal), 10 (hDAT WT 
AMPH, rDAT WT AMPH, A558V rDAT AMPH), 9 (hDAT WT PMA, A559V 
hDAT PMA), 22 (A558V rDAT basal), 13 (rDAT WT PMA), 23 (A559V hDAT 
basal); n=number of cells analyzed). Statistical analyses were done by unpaired 
Student’s t-test using graphpad prism.  
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failed to show a significant AMPH-induced shift in its lateral mobility, from its 
already increased level of lateral membrane mobility (lower T ½ values) which is 
similar to the mobility for WT upon AMPH treatment (T ½: hDAT WT (basal), 42 + 
4; hDAT (AMPH), 24 + 4; hDAT (PMA), 21 + 5; A559V hDAT (basal), 24 + 2; 
A559V hDAT (AMPH), 20 + 3; rDAT WT (basal), 40 + 4; rDAT (AMPH), 18 + 2; 
rDAT (PMA), 20 + 3; A558V rDAT (basal), 21 + 2; A558V rDAT (AMPH), 20 + 3). 
Here we see an increase in lateral membrane mobility for palmitoylation deficient 
mutants. With AMPH or PMA-stimulation indirectly reducing palmitoylation, we 
believe palmitoylation is the driving force for lateral membrane mobility. For A559V 
hDAT, the Ala to Val substitution at 559 position could be the driving force for alter 
palmitoylation, which could lead to increased lateral membrane mobility further 
driving phosphorylation and membrane raft distribution, affecting DAT’s trafficking 
ability from the plasma membrane into the cytosol and altering lateral mobility within 
the plasma membrane [71, 215, 216].  
Palmitoylation is a factor affecting lateral membrane mobility 
S-Palmitoylation is known to affect various cellular factors and DAT transport 
regulation [36]. Thus we also anticipated lateral membrane mobility to be one of the 
factors that is affected by palmitoylation as it is a lipid modification and its presence 
could lead to restricted lateral mobility. In order to understand if palmitoylation plays 
a role in lateral membrane mobility, we examined lateral membrane mobility upon 
2BP treatment, an irreversible PAT inhibitor, which prevents palmitoylation.  
N2A cells transiently expressing YFP-tagged WT hDAT were treated with vehicle or 
15 μM 2BP for 3 hours, followed by FRAP analysis (Fig. 23). 2BP treatment resulted 
in an increase in lateral membrane mobility (lower T ½ values) for WT (T ½: hDAT  
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Figure 23: Inhibition of DAT palmitoylation results in increased lateral membrane 
mobility. 
N2A cells transiently expressing YFP-tagged WT hDAT was treated with vehicle or 15 
μM 2BP for 3 hours followed by FRAP analysis. The recovery curves display the 
fluorescence recovery for DAT after photobleaching in the absence or presence of 2BP 
treatment. The histogram shows the quantification of the time taken (sec) by each 
DAT to recover post photobleaching (Time of Recovery (sec), mean + S.E.; * p < 
0.01, WT (2BP) vs. WT (basal); n=20 (hDAT WT basal), 13 (hDAT WT 2BP); 
n=number of cells analyzed). Statistical analyses were done by unpaired Student’s t-
test using graphpad prism. 
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WT (basal), 41 + 4; hDAT (2BP), 20 + 3). With 2BP having no known ability to 
activate PKC or other kinases [217], we were able to show that palmitoylation is a 
factor regulating lateral membrane mobility. However, this decreased palmitoylation 
also leads to increased phosphorylation in a reciprocal manner making it difficult to 
determine which is a major driving factor. 
Phosphorylation deficient mutants display decreased lateral membrane mobility 
Previous studies have shown that DAT undergoes reciprocal regulation of 
phosphorylation and palmitoylation [110]. With palmitoylation being a factor driving 
lateral membrane mobility, we examined the lateral membrane mobility for 
phosphorylation deficient mutants display increased palmitoylation levels [110] 
[Chapter II]. N2A cells transiently expressing YFP-tagged WT, T53A rDAT, S7A 
hDAT or S53A hDAT (human homologue for T53A rDAT) were subjected to FRAP 
analysis (Fig. 24). In contrast to WT, T53A rDAT, S7A hDAT and S53A hDAT 
showed a decrease in lateral membrane mobility (higher T ½ values) (T ½: hDAT WT, 
38 + 4; rDAT WT, 38 + 5; S53A hDAT, 53 + 51; S7A hDAT, 66 + 11; T53A rDAT, 
61 + 10). Thus phosphorylation deficient mutants displayed decreased lateral 
membrane mobility. We believe a reciprocal increase in palmitoylation in these 
mutants leads to this decrease in lateral membrane mobility.   
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Figure 24: Phosphorylation deficient mutants display decreased lateral membrane 
mobility. 
N2A cells transiently expressing the indicated YFP-tagged hDAT or rDAT forms were 
subjected to FRAP analysis. The recovery curves display the fluorescence recovery for 
each DAT line after photobleaching. The histograms show the quantification of the 
time taken (sec) by each DAT to recover post photobleaching (Time of Recovery 
(Sec), mean + S.E.; * p < 0.005, indicated DAT forms vs. WT; n=25 (hDAT WT), 19 
(rDAT WT, S7A hDAT), 22 (S53A hDAT), 12 (T53A rDAT); n=number of cells 
analyzed). Statistical analyses were done by unpaired Student’s t-test using graphpad 
prism.   
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DISCUSSION 
DAT plays an important role in maintaining DA homeostasis thus controlling the 
clearance of DA from the synapse. Dopaminergic signaling modulates brain activities 
such as pleasure, motor and cognitive behavior, attention and sleep patterns [2, 3]. 
DAT, like other transporters is targeted by drugs such as AMPH and COC which 
affects the overall function of DAT resulting in an increase in synaptic levels of DA 
[2, 3, 205, 206]. AMPH is known to mediate PKC-stimulated DAT phosphorylation 
which is associated with DA efflux. A SNP in hDAT associated with ADHD, A559V 
hDAT displays anomalous DA efflux (ADE) and increased phosphorylation 
independent of AMPH stimulation [8, 9, 40, 57, 202, 212] [Chapter II]. With PKC-
stimulated phosphorylated DAT enriched in membrane raft regions our study showed 
A559V hDAT, and its rat homologue, A558V rDAT have increased membrane raft 
microdomain localization. This increased localization was independent of AMPH 
stimulation, which in WT induced a shift towards membrane raft localization. With 
rafts being the primary site for DAT phosphorylation and/or phosphoylated DAT 
localization, we believe membrane rafts serve as a platform for ADE, possibly by 
increased interaction with raft localized binding partners such as Syntaxin 1A (Syn 
1A). Thus membrane rafts could play a role in compartmentalization affecting overall 
DAT function and could be associated with various neurological disorders [56, 90, 
137, 172, 175, 213, 214]. With studies showing DAT undergoing reciprocal regulation 
for phosphorylation and palmitoylation, A559V hDAT, reciprocally showed lower 
levels of palmitoylation [Chapter II]. This shows that these post-translational 
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modifications together play a role in affecting the membrane raft distribution, with 
phosphorylated DAT aggregating in the membrane raft regions, possibly due to 
increased interaction with binding partners and palmitoylation helping in membrane 
raft partitioning by having stable membrane anchoring and integral membrane protein 
interaction [30, 56, 110, 111, 218].  
An important factor in proper DAT function is the membrane trafficking of DAT on 
the plasma membrane and towards internalization which is affected by these post-
translational modifications. Dysregulation of membrane trafficking is associated with 
many neurological disorders [167, 172]. With palmitoylation affecting membrane 
mobility and membrane trafficking, our study showed increased lateral membrane 
mobility for A559V hDAT and other palmitoylation deficient mutants with opposite 
results for phosphorylation deficient mutants. 
With AMPH and PMA-mediated increases in DAT phosphorylation and 2BP-
mediated decreases in DAT palmitoylation increasing lateral membrane mobility in 
WT DAT, we believe palmitoylation to be the driving force for this change in 
membrane mobility. We believe, for A559V hDAT, the substitution of Val for Ala in 
close proximity to the palmitoylation site may be the reason for the decrease in 
palmitoylation. A559 is located at the top extracellular side of TMD 12 and C581 is 
located at the bottom intracellular side of TMD 12 and the bulkier Val substitution 
may cause structural changes within TMD 12. This change could make C581 move 
away from the DAT core region making it lose its flexibility also affecting C581’s 
ability to cap at the cytoplasmic gate. Thus this altered palmitoylation status of A559V 
hDAT and A558V rDAT which could affect its phosphorylation status by an unknown 
mechanism which stimulates ADE.  
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This decreased presence of saturated fatty acid moiety (palmitate) could affect DAT’s 
interaction with binding partners and cholesterol leading to altering its membrane 
distribution and function, causing an increase in lateral membrane mobility. This in 
turn could be the driving force for an increase in phosphorylation leading to 
localization of phosphorylated DAT in membrane raft microdomains, potentially 
serving as a platform for ADE. We believe other phosphorylation or palmitoylation 
deficient mutants might show similar unknown mechanisms, so as to show reciprocal 
regulation of these post-translational modifications.  
Currently our knowledge is limited on understanding how these modifications affect 
lateral membrane mobility and microdomain localization, but our study provides 
valuable insights. 
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